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ABSTRACT 
RATIONAL DRUG THERAPY MONITORING IN TYPE 2 DIABETES MELLITUS: 
USING GLYCATED HAEMOGLOBIN AS A GUIDE FOR CHANGE IN THERAPY 
Type 2 diabetes mellitus is a progressive disease characterised by defects in insulin secretion, 
insulin action or both. Proper management of diabetes with appropriate drug and lifestyle 
interventions, guided by proper glycaemic monitoring has shown improved glycaemic control 
and a substantial decrease in morbidity associated with complications and mortality. 
Evidence-based guidelines for the appropriate management of diabetes, suggests the use of 
glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) as monitoring indicators 
and have set targets levels that indicate appropriate glucose control. In the event of 
suboptimal control, actions steps to adjust pharmacotherapeutic treatment has been set out. Of 
the two aforementioned glycaemic monitoring indicators, HbA1c is termed the ‘gold 
standard’ as it provides the most comprehensive data i.e. it reflects both fasting and 
postprandial glucose concentrations over a 3 months period as compared to FPG which only 
show glucose levels for a few hours.  
The aim of this study was to describe the use of glycaemic monitoring indicators in patients 
with type 2 diabetes mellitus, classified as stable, treated at primary health care facilities in 
the Cape Town Metropolitan Region in South Africa. The study was a descriptive, 
retrospective and quantitative in design. Data were collected from patient medical records 
and included glycaemic monitoring tests and results as well as prescribing records for a 
maximum period of 18 months. 
The study comprised of 575 participants from five primary health care facilities in the 
Western Cape Metropole region. All participants had FPG results, while HbA1c results were 
recorded for 86% of participants at least once. More than 70% of participants with either a 
FPG or HbA1c result showed suboptimal glucose control i.e. were outside of the target range. 
In 181 opportunities for intervention in participants with HbA1c results outside target, 113 
(62.4%) did not have any therapy adjustments, 19 (10.5%) had the total daily dose increased, 
6 (3.3%) had total daily dose decreased, 9 (5.0%) had a step-up in regimen, 5 (2.8%) had a 
step down in regimen and 29 (16.0%) had a lateral regimen change. In 852 opportunities for 
intervention in participants with FPG results outside target, 609 (71.5%) did not have any 
therapy adjustments, 47 (5.5%) had the total daily dose increased, 18 (2.1%) had the total 
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daily dose decreased, 16 (1.9%) had a step-up in regimen, 15 (1.8%) had a step down in 
regimen and 147 (17.3%) had a lateral change in regimen. 
This study has demonstrated  that in the primary healthcare facilities investigated, FPG was 
the most often used gycaemic monitoring indicator, glycaemic monitoring of patients  mostly 
show suboptimal glucose control and that opportunities to optimise pharmacotherapy in 
diabetes management are mostly missed.  
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CHAPTER 1: INTRODUCTION 
1.1  INTRODUCTION 
The focus of this dissertation is on the use of HbA1c results, as the main glycaemic control 
indicator together with other monitoring parameters, on the therapeutic management of type 2 
diabetes mellitus patients attending primary health care facilities in the Western Cape 
province of South Africa. The main focus is on patients classified as stable which implies 
good glycaemic control and /or low risk for developing complications by using retrospective 
patient data. 
1.2  BACKGROUND TO THE STUDY 
Non-communicable diseases (NCDs) are diseases that progress slowly over a long period of 
time and are non-infectious in nature (Puoane et al. 2013). NCDs mainly consist of 
cardiovascular diseases, cancers, respiratory diseases and diabetes. When combined together 
they are the leading causes of mortality globally (Department of Health (DoH) 2013).  
Three hundred and forty seven million people were reported to have been affected by 
diabetes mellitus (DM) in 2008 globally (Danaei et al. 2011), with an estimate that this 
number will increase to 366 million people in 2030 (WHO 2010). The World Health 
Organization (WHO) (2010) further stated that in 2000, 814 000 people were affected by DM 
in South Africa (SA) and this number is expected to increase to 1-1.5 million people in 2030 
(WHO 2010). Currently the prevalence of DM in SA is estimated at 9.0% in adults aged 30 
years and older (Bertram et al. 2013).    
There are several factors contributing to this predicted increase in NCDs, which include rapid 
epidemiological transition of people from rural to urban areas, ultimately resulting in physical 
inactivity and unhealthy eating habits which serve as the link to chronic diseases of lifestyle 
such as type 2 diabetes mellitus (Peer et al. 2012). Ageing populations, obesity and ethnicity 
are also associated with the observed increased prevalence posing a major burden on the 
patient’s well-being and financial security. An increase in NCDs also increases the burden on 
health care service delivery and medical expenditure (Peer et al. 2012). Treatment of chronic 
diseases puts much strain on the already overburdened health system, because of the 
additional resources required. 
1.3 PROBLEM STATEMENT  
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Despite the evidence that shows the benefits of attaining glycaemic goals of therapy and costs 
diabetes incurs, the management of diabetes is still suboptimal globally (Zhang et al 2000). 
Del Prato and associates (2005) stated that more than  60% of patients are not reaching 
glycaemic targets, and urgent steps are required in order to increase the proportions of 
patients achieving their glycaemic goals to reduce the risk of complications  (Del Prato et al. 
2005). The study conducted on microvascular complications in Durban South Africa in the 
Indian population, showed that patients who have long-duration diabetes mellitus, 64.5% had 
retinopathy, 25% had persistent proteinuria and hypertension was observed in 86% of the 
patients (Motala 2013). In the group that was diagnosed as patients with type 1 diabetes, 
retinopathy was found in 53.2% of patients, persistent proteinuria was found in 23% and 
hypertension in 34% indicating a high prevalence of microvascular complications (Motala 
2013).   
Management of DM requires a multi-disciplinary approach which involves patient 
participation, health personnel and other T2DM patients (Pawaskar et al. 2007). Inconsistent 
patient follow-ups, non-adherence to anti-diabetic medication and failure of physicians to 
change therapy plays a major role in patient outcomes (Wetzler & Snyder 2000). In attaining 
individualised glycaemic target usually requires the use of multiple anti-diabetic medications 
which increase adverse drug reactions affecting patient adherence. Adverse effects include 
weight gain and hypoglycaemia associated with the use of insulin or sulphonylureas and 
gastrointestinal side effects with metformin (Ismail-Beigi et al. 2011).  
With regards to health care personnel, patient follow-up and therapy adjustments are 
important when HbA1c levels are ˃8%. However, considerable variations in the regularity of 
follow ups and therapy adjustment persist (Society for Endocrinology, Metabolism and 
Diabetes of South Africa (SEMDSA) 2012; American Diabetes Association (ADA) 2014). 
The inconsistent use of HbA1c in monitoring and guiding treatment change by physicians in 
T2DM patients compromises the quality of care. HbA1c ≥8% is a proven risk factor for the 
development of microvascular complications and poor quality of life in individuals with 
diabetes (Zhang et al. 2000). Every 1% increase in HbA1c is associated with a 38% risk of 
macrovascular event, a 40% risk in microvascular event and a 38% risk of death (Zoungas et 
al. 2012).    
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1.4  RESEARCH QUESTIONS 
The following research questions can be formulated based on the forgoing discussion: 
• Is HbA1c used as the main glycaemic control indicator? 
• How are the results of monitoring indicators used and responded to? 
• Are the patients maintaining their glycaemic control? 
• Are therapy adjustments based on the results of the monitoring indicators? 
1.5  PRIMARY AIM AND OBJECTIVES 
The primary aim of this study was to describe the use of glycaemic monitoring indicators in 
patients with type 2 diabetes mellitus, classified as stable, treated at primary health care 
facilities in the Cape Town Metropolitan Region in South Africa. 
Specific objectives were to: 
• Describe glycated haemoglobin and fasting plasma glucose results according to risk 
stratification as per evidence-based management guidelines.   
• To assess if treatment regimens and adjustments are done in accordance with glycated 
haemoglobin and fasting plasma glucose results as per evidence-based management 
guidelines.  
1.6 RESEARCH METHOD  
The research method consists of two sections in conjunction with the specific research 
objectives, namely a literature review and an empirical investigation. 
 
1.6.1 Literature review 
The aim of the literature review is to identify methods that are implemented internationally 
and nationally to monitor the glycaemic control indicators in type 2 diabetes mellitus patients. 
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A discussion on the management of diabetes mellitus will also form part of the literature 
review. 
1.6.2  Empirical investigation 
The empirical investigation constitutes several steps, namely: the selection of the research 
design, the composition of the research population, the selection and application of the 
criteria and measuring instruments for data analysis, data application and data analysis, 
reliability and validity, the report and discussion of the empirical investigation, and the 
conclusion recommendations based on the results of the empirical investigations as well as 
the limitations of the investigations. 
1.6.3 Report and discussion of the results of the empirical investigations 
The report and discussion of the results of the investigation are illustrated graphically and in 
tables, in order to ensure clarity and to achieve the set aims of the investigation. 
1.6.4 Conclusion, recommendations and limitations of the study 
The conclusion of the study, based on the results of the literature review and investigation, as 
well as the recommendations derived from this study on the use of glycaemic monitoring 
indicators in patients with type 2 diabetes mellitus will be discussed in chapter 7. Attention 
will be brought to the limitations encountered during the study throughout chapters 2, 3 and 4 
with further detailed discussion of these limitations in chapter 6. 
1.7 DIVISION OF CHAPTERS  
The division of chapters will be as follows: 
Chapter 1: Introduction 
Chapter 2: Health in South Africa 
Chapter 3: Diabetes mellitus 
Chapter 4: Methodology 
Chapter 5: Results 
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Chapter 6: Discussion and limitations of the study 
Chapter 7: Conclusions and recommendations  
1.8 CHAPTER SUMMARY 
In this chapter the problem statement, research questions and objectives, research method and 
division of chapters were discussed.      
In the following chapter health in South Africa will be discussed.   
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CHAPTER 2: HEALTH IN SOUTH AFRICA  
2.1 OVERVIEW OF THE CHAPTER  
In this chapter, healthcare in general is discussed, which includes different types of healthcare 
as well as the way in which healthcare services are rendered and facilitated in various settings 
in South Africa with emphasis on the Western Cape. The distinction between private and 
public healthcare will be discussed with more focus on the public health sector. Burden of 
disease and its impact on the health sector will be discussed. Lastly the discussion will be 
focused on healthcare and concepts which will include; Health Framework, National Core 
Standards and National Drug Policy.   
2.2 INTRODUCTION 
In South Africa, the increasing cost of healthcare has become problematic for all health care 
stakeholders, including patients. This escalation in healthcare spending is due to increased 
life expectancy, increased patient expectations, higher standards of living and more demand 
for health care quality and services which is worsened by the observed quadruple burden of 
the disease (Dhamend 2011). The South African government also realises the importance of 
health care and therefore remains one of the South African Government’s main concerns, 
particularly since the current system has been described as failing to produce a successful 
health care outcome pre and post-1994 (Matsoso & Fryatt 2013).  
The Department of Health has therefore set out a ten-point plan to address current healthcare 
shortcomings and established a workable healthcare system in South Africa (Department of 
Health (DoH) 2011). The ten point plan are: 
• Provision of strategic leadership and creation of a social compact for better health 
outcomes 
• Implementation of National Health Insurance (NHI) 
• Improving the quality of health services 
• Overhauling the health care system and improving its management 
• Improving human resource management, planning and development 
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• Revitalisation of infrastructure 
• Accelerated implementation of HIV/AIDS and Sexually Transmitted Infections and 
increased focus on TB and other communicable diseases 
• Mass mobilisation for better health for the population 
• Review of the National Drug Policy 
• Strengthening research and development 
Although healthcare includes many aspects and elements as illustrated in the ten-point plan, 
the important area of healthcare to be highlighted in this chapter is that of improving the 
quality of health services for better health outcomes with regard to burden of disease. 
Implementing a successful health care system that addresses all the healthcare needs of the 
patient as set out in the ten-point plan is seen as a South African priority, and this chapter 
aims to further explore the various elements of healthcare and specifically the burden of the 
disease and its impact in the public health sector facilities. The focus will specifically be on 
quadruple burden of diseases which encompasses, HIV and AIDS epidemic, tuberculosis, 
maternal and child mortality, Intentional and non-intentional injuries and non-communicable 
diseases. This is also in-line with the government’s objective of “a long and healthy life for 
all” (DoH 2013). To further address this, the government is in the process of establishing the 
national health insurance (NHI) to increase and promote access to healthcare through the 
establishment of the following goals (DoH 2011):  
• provide improved access to quality health services for all South Africans irrespective 
of whether they are employed or not 
• pool risks and funds so that equity and social solidarity will be achieved through the 
creation of a single fund 
• procure services on behalf of the entire population and efficiently mobilise and 
control 
• strengthening of the financial resources to help contain costs 
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• Strengthen the under-resourced and strained public sector to improve health systems 
performance. 
2.3 HEALTHCARE DELIVERY 
The World Health Organisation (WHO) (2000), in its 2000 World Health report, defines a 
healthcare system as follows: 
“Health systems consist of all the people and actions whose primary purpose is to improve 
health. They may be integrated and centrally directed, but often they are not. After centuries 
as small-scale, largely private or charitable, mostly ineffectual entities, they have grown 
explosively in this century as knowledge has been gained and applied. They have contributed 
enormously to better health, but their contribution could be greater still, especially for the 
poor. Failure to achieve that potential is due more to systemic failings than to technical 
limitations. It is therefore urgent to assess current performance and to judge how health 
systems can reach their potential”. 
The World Health report (WHO 2000) describes a good health system, most importantly, as 
contributing to good health. It further explains a health system as an organisation with a 
series of activities with the same aim of improving; maintaining and restoring health for the 
population it serve, being service providers, funders, policy makers or administrators. The 
health system therefore has the responsibility of emphasising prevention and promotion to 
improve on elements that can be prevented and not neglect care and treatment to improve 
health outcomes (NCD strategic plan 2013-17). 
2.4 SOUTH AFRICAN HEALTHCARE SYSTEM 
Governments of countries have different perspectives on how to achieve good healthcare 
service to all patients. In response to accessible quality healthcare the government of South 
Africa proposed to establish national health insurance. Tanner (2008) agrees that there are 
different health care models followed and used across the world. Each country’s health care 
system is a result of “its unique conditions, history, politics, and national character”, and 
many are undergoing reform. For example Canada uses a single payer system while Germany 
uses employment based system insurance for its people (Tanner 2008). South Africa seems to 
have a combination between a single payer system, where the government pays for all 
medical needs (i.e. SA public health sector), and a managed competition system, where the 
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private sector can charge within a regulated environment and patients are free to choose 
which medical scheme to belong to (Erusmus 2011).     
According to Schaay & Sanders (2008) there are three areas of serious concern in the SA 
healthcare system: 
• A significant increased burden of disease related to HIV/AIDS 
• Notable weakness in certain areas of health system management 
• A low level of health outcomes when compared to the country’s expenditure on 
healthcare 
Peltzer (2009) found that, of all South African patients who received in-patient care, 72.2% 
attended a public and 24.3% a private facility. Of patients who received outpatient care at a 
facility, 58.7% attended a public and 35.7% a private facility. This shows that the public 
sector is more utilised than the private sector.  
2.4.1 Public healthcare in South Africa 
South Africa has a two-tiered health care system with separate public and private streams. 
The public health sector is however, stretched and under-resourced, generally funded by tax 
covering 85% of the population and the remainder of the population covered by the private 
health sector (Presidency 2006). It can generally be stated that the public healthcare system in 
South Africa is not a successful one, based on various measurements. Kleinert and Horton 
(2009) found that South Africa spends more on health than any other African country at 8.7% 
of its gross domestic product (GDP). This is similar to the healthcare spending in Sweden 
(8.9% of GDP).Yet South Africa is one of only 12 countries worldwide in which maternal 
mortality and mortality for children younger than 5 years have actually increased since 1990 
(Kleinert & Horton 2009). 
Econex (2013) showed that in 2013 infant mortality rate was estimated at 41.7 per 1000 live 
births, while maternal mortality rate was estimated to be 333 per 100 000 live births in 2009. 
This emphasizes the fact that South African health system performs poorly when comparing 
its impact on the health status of the nation to countries with a similar or poorer per capita 
GDP (Kleinert & Horton 2009). Life expectancy was estimated to be 70 years in 2011 
globally while in 2013 life expectancy was estimated at 57.7 years for males and 61.4 years 
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for females in South Africa. This is largely from high prevalence of HIV, which was 
estimated at 10% with 5.26 million people living with HIV in 2013. Tuberculosis and non-
communicable diseases are also contributing to the observed low life expectancy rates, these 
indicates that the South African healthcare faces overwhelming challenges (Econex 2013). 
This viewpoint is further supported by Econex research which found that the poorest 
households, who are eligible for free public health care, pay considerable sums for private 
health care. They found that user dissatisfaction in the public sector were mostly due to long 
waiting times, unobtainable medication and rude medical staff. In the private sector, 
dissatisfaction was mainly due to the perceived high price of the services (Econex 2010). 
According to a comparative study of the quality of health systems in 48 developed and 
developing countries in 2008, it was found that South Africa’s public sector ranked eighth 
from the bottom, while the private sector ranked sixth from the top (Econex 2010). 
Poor health services in the public health sector are worsened by the rising prevalence of non-
communicable diseases. Isaac et al (2014) showed that the ratio of chronic conditions to those 
of acute conditions was 82%: 18%, the study findings also indicate that most adults attending 
public sector facilities in the Western half of the Cape Town Metropole had chronic 
conditions. The cost of treating these conditions was significantly greater than that of treating 
acute conditions and estimated to be second to human resource (57%) and medicine cost were 
found to be 19% or R132 million (Isaacs et al. 2014).  
The Department of Health indicated in its strategic plan for 2010-13 that it intends to 
establish a National Health Insurance (NHI) system as part of its health reform process. The 
aim of the NHI was to improve the financing and delivery of “an efficient, equitable, and 
sustainable health care system in pursuit of universal health care for all” (DoH 2010). The 
proposed NHI system focused on developing an essential health care package, the creation of 
an NHI fund to provide financial resources and defining the role of private funders and 
providers in the system (DoH 2010).  
In the Green Paper on NHI released in August 2011, it was stated that the NHI will offer all 
South Africans and legal residents access to a defined package of comprehensive health 
services. It will also offer care at all levels, from primary health care to specialized secondary 
care, and highly specialized tertiary and quaternary levels of care (DoH 2011).  
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According to the NHI Policy Document (DoH 2011a), quality of service was to be ensured 
by: 
• A radical improvement in the quality of services in the public health facilities. This 
means massive investment in improvement of health infrastructure, both buildings 
and equipment. 
• Compliance to certain basic standards, and the creation of an overseeing body called 
the Office of Health Standards Compliance. 
• A great improvement to public health care management. This was to be achieved as 
part of the 10-point program and speaks of a complete overhaul of the health care 
system. 
According to a KPMG report investigating the impact of NHI in South Africa, economic 
benefit estimates illustrate that a one year increase in a nation’s average life expectancy can 
increase GDP per capita by 4% in the long run. Having a healthier labour force can also result 
in increased productivity. Based on international studies, labour force productivity can 
increase between 20% and 47.5% (DoH 2011b) as illustrated in Table 2.1. 
Table 2.1 Public health expenditure of various countries expressed as various ratios 
(KPMG 2011) 
Country Public Expenditure 
on health as % of GDP 
Public Health 
Expenditure as a % of 
total Government 
Expenditure 
Public Health Expenditure per 
capita PPP (constant 2005 prices, 
US$) 
 2007 2008 2009 2007 2008 2009 2007 2008 2009 
Australia 5.56 5.56 5.56 17.10 17.10 17.10 2 190.38 2 200.64 2 211.92 
Brazil 3.51 3.72 4.13 5.37 5.96 6.08 342.13 385.33 430.82 
Canada 6.70 6.84 7.50 17.11 17.19 17.01 2 573.52 2 688.39 2 882.95 
China 1.92 2.05 2.29 10.27 10.27 10.27 106.13 125.62 155.04 
India 1.21 1.35 1.37 4.06 4.41 4.06 33.48 39.51 43.14 
Russia 3.45 3.10 3.51 10.21 9.17 8.53 580.96 633.26 668.74 
South Africa 3.45 3.27 3.41 11.06 10.39 9.27 336.72 334.44 345.72 
United Kingdom 6.91 7.16 7.81 15.65 15.12 15.12 2 465.16 2 662.19 2 842.59 
United States 6.97 7.26 7.88 19.00 18.73 18.68 3 239.53 3 425.90 3 602.45 
Key:  GDP-Gross Domestic Product 
 PPP- Purchasing Power Parity 
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Table 2.1 shows that in terms of public health expenditure as a percentage of GDP and public 
health expenditure as a percentage of total government expenditure, South Africa is 
comparable with countries such as Russia and Brazil. However, in terms of the public health 
expenditure per capita, South Africa compares poorly with countries such as Australia and 
the United Kingdom, where there are national health systems. 
2.4.2 Private healthcare in South  Africa 
The private sector serves only 16% of the population yet consumes over 50% of the total 
healthcare spending in South Africa. It would seem that although public health care is 
provided mostly free of charge to users of public health services, private health care users are 
responsible for the bulk of their own medical expenses in the form of payments to medical 
schemes and this is from members predominantly from the high income groups, formally 
employed. The government funds private healthcare through specialised insurance funds, for 
example the road accident fund and workmen’s compensation (Econex 2013).  
The private healthcare which is also an essential tool to the right of access to health care 
(Francis 2013) produced the health outcomes in 2008 that were ranked alongside the 
healthcare sectors of countries such as Australia, Sweden, Belgium, Switzerland and Ireland 
(Econex 2013). The linkage of the private sector with the public sector is a health system 
success even though the huge load on the health system increases as HIV/AIDS and TB 
transits to becoming chronic diseases requiring lifelong treatment and care (Coovadia et al 
2009). 
2.5 HEALTH FRAMEWORK 
According to WHO (2007) health systems framework consists of all organizations, people 
and actions whose primary interest is to promote, restore or maintain health. For example, all 
health systems have to provide services, develop health workers, mobilize and allocate 
finances, ensure health system leadership and governance. Framework is meant to measure 
performance, understand the factors that contribute to it, improve it, and respond better to the 
needs and expectations of the people within the country (Schaay et al 2011). Figure 2.1 
illustrates the WHO health system framework building blocks.  
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Figure 2.1 The World Health Organisation system framework building blocks (WHO 
2007) 
 
2.5.1 Service Delivery  
Service delivery refers to what the system does not what it is, it also refers to the way inputs 
such as money, staff, equipment and drugs are combined to allow the delivery of health 
interventions with minimum waste of resources (WHO2000).  
2.5.2 Health Workforce 
Health workforce involves making use available multi skilled personnel, more especially in 
disadvantaged areas and strategies to retain personnel, to ensure equity and accessibility of 
health services for patients (WHO2007). 
2.5.3 Information  
Health information is used by policy-makers, planners, health care providers, development 
partners and the general public to track health-system performance, to support better health 
policies and make effective health-related decisions; it is a national asset (WHO2007).  
2.5.4 Medical products, vaccines & technologies 
Essential medicines should always be available at affordable costs to individuals and systems. 
They should be in adequate amounts, in the appropriate dosage and in good quality. They 
should be selected based on efficacy, safety and cost effectiveness (WHO2007) 
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2.5.5  Financing  
The goal of health financing is to ensure adequate spending on health and effective allocation 
of financial resources to different types of public and personal health services. Health 
financing is important in analysing health policies, sources of funds and effectiveness of 
health services delivered to the population (WHO2007). 
2.5.6 Leadership / governance 
Health governance refers to the wide range of functions carried out by governments to 
improve population health while ensuring equity in access to services, quality of services, and 
patients' rights (WHO2007). 
The South African health framework has been formulated in-line with the WHO framework 
for strengthening and assessing the performance of health systems (Schaay et al 2011). Figure 
2.2 shows the national health framework of South Africa  
   
 
Figure 2.2 The national health framework of South Africa (Adopted from Schaay et al 
(2011)) 
Figure 2.2 shows that for a health system to be able to measure its performance and achieve 
its objectives which are delivery of accessible, equitable and good quality health services 
which addresses the demands of the citizens, the national health system has to embark on a 
number of activities. For example, ensuring appropriate stewardship; developing human 
resources for health; mobilising and allocating adequate finances; developing and 
maintaining a well-functioning health information system and ensuring equitable access to 
essential medical products, vaccines and technologies (Schaay et al 2011). 
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2.6 NATIONAL CORE STANDARDS 
The importance of good quality care in patients and monitoring of the outcomes of healthcare 
was facilitated through the establishement of the National Core Standards by National 
Department of Health. The National Core Standards are tools used to achieve, guide and 
monitor the quality of health outcomes in both the patients and personnel and also the health 
establishments (National Department of Health (NDoH) 2011).  
The following objectives were set to achieve this:  
• To develop a benchmark of quality care which should be found in all health centres 
across the country. 
• To develop a monitoring system which will assess all health establishments, identify 
gaps and appraise improvements. 
• Certification of health establishments with set standards (NDoH 2011)   
The Department of Health has also developed seven domains of national core standards 
which are areas of potential risk and therefore needs attention (Connell 2014), these are 
• Patient rights 
• Patient safety, clinical governance and care 
• Clinical support services 
• Public health 
• Leadership and corporate governance 
• Operational management 
• Facilities and infrastructure 
Each domain is further sub-divided into sub-domain to make the main domains easily 
implemented and monitored, the first three domains dealt with the main business of the health 
system which is delivering quality health care to patients, and health outcomes while the last 
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four domains deals with ensuring that the core business is easily implemented  (Schaay et al 
2011) Table 2.2. 
Table 2.2 The domains and sub-domains of the Department of Health 
Domain Sub-domain 
Domain 1: Patient Rights Respect and dignity 
Information to patients 
Physical access 
Continuity of care 
Reducing delays in care 
Emergency care 
Access to package of services 
Complaints management 
Domain 2: Patient Safety, Clinical Governance and 
Care 
Patient care 
Clinical management for improved health outcomes 
Clinical leadership 
Clinical risk 
Adverse events 
Infection prevention and control 
Domain 3: Clinical Support Services Pharmaceutical services 
Diagnostic services 
Therapeutic and support services 
Health technology services 
Sterilisation services 
Mortuary services 
Efficiency management 
Domain 4: Public Health Population-based service planning and delivery 
Health promotion and disease prevention 
Disaster preparedness 
Environment control 
Domain 5: Leadership and Corporate Governance Oversight and accountability 
Strategic management 
Risk management 
Quality management 
Effective leadership 
Communications and public relations 
Domain 6: Operational Management Human resource management and development 
Employee wellness 
Financial resource management 
Supply chain management 
Transport and fleet management 
Information management 
Medical records 
Domain 7: Facilities and Infrastructure Buildings and grounds 
Machinery and utilities 
Safety and security 
Hygiene and cleanliness 
Linen and laundry 
Food services 
Adopted from Whittaker et al 2011 
Although healthcare with regard to national core standards includes many facets and elements 
as illustrated in the domains and their sub-domains the current chapter is interested in the first 
four domains which deals specifically with the health system concepts.  
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2.7 TYPES OF HEALTHCARE 
The WHO (1948) defines health as “a state of complete physical, mental and social well-
being and not merely the absence of disease or infirmity”. 
A health system focuses on the health of people and consists of many components (World 
Bank 2007). The functions of a health care system are service provision, and also regulation, 
policy creation and management of resources (human or medical products such as medication 
or equipment). It is the responsibility of, among others, ministries of health, health care 
providers and organisations, pharmaceutical companies and health care funders. A health care 
system influences the lives of patients and their families in the broader community (World 
Bank 2007). Marmor & Wendt (2012) define health care as “the work that patients, doctors, 
nurses, druggists, and hospitals do when facing real or feared illness”. 
Berry & Mirabito (2010) describe the basic functions of a health care system as including 
primary care, doctors’ visits, inpatient treatments and tests (ambulatory care) as well as 
emergency treatment.  
2.7.1 Primary health care 
According to the WHO’s Primary Care Division (WHO 2010), the main goal of primary 
healthcare is better health for all. The five elements needed to achieve this goal are: 
• reducing exclusion and social disparities in health  
• organizing health services around people's needs and expectations  
• integrating health into all sectors  
• pursuing collaborative models of policy dialogue (leadership reforms) 
• increasing stakeholder participation 
Primary care is defined by Rothman & Wagner (2003) as “the provision of integrated, 
accessible health care services by clinicians who are accountable for addressing a large 
majority of personal health care needs, developing a sustained partnership with patients and 
practicing within the context of family and community”. Majority of chronic illnesses are 
managed in primary health care.  This was evident in the United States of America where by 
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90% of diabetic patients were managed in the primary care indicating that efforts in 
improving primary care must be maintained (Rothman & Wagner 2003).    
In South Africa, the concept of primary health care (PHC) emerged during the 1970s when 
health care concepts began to change generally and specifically in relation to the developing 
world (Schaay & Sanders 2008). The development of community orientated primary care in 
South Africa led to more focus on outreach beyond hospitals to more outlying health centres. 
This even reached out as far as individual households. South Africa like the developed 
countries more patients seen in the primary health care facilities are patients with chronic 
illnesses. This was evident in the Western Cape where 23 395 hypertensive and 13 338 
diabetic patients attend primary health care services monthly (Parker et al 2012). 
Department of Health’s 10-point plan in addressing the current shortcomings established a 
workable healthcare system in South Africa which looked at, revitalisation of primary health 
care entailing completion of the audit of primary health care infrastructure and services, 
acceleration of infrastructure delivery of primary level facilities, and refurbishment and 
preventative maintenance of all hospitals. The plan was that “district teams” were to be 
appointed to manage the primary health care facilities in each of the 52 districts (DoH 2010). 
Schaay et al. (2011) state that the primary health care system in SA has failed to reach several 
goals and standards over the past years and describe the envisaged primary health care re-
engineering as follows (Schaay et al 2011): 
• Greater focus on the delivery of community-based services, with an emphasis on 
disease prevention, health promotion and community participation. This will not only 
cure but also prevent. These outreach activities are to be performed by a primary 
health care outreach team consisting of nurses and community health workers, who 
are supported by facility-based and specialist support teams of health professionals. 
• Greater attention will be given to those factors outside the health sector that impact on 
health (social factors influencing health). 
2.7.2 Ambulatory care 
Stedman’s Medical Dictionary (2013) describes ambulatory care as “medical or surgical 
health treatment provided during an episode of care that does not require an overnight stay in 
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a medical facility and from which the patient goes home; outpatient rather than inpatient 
care”. According to Eggli et al. (2006) ambulatory care is a growing avenue for health care in 
Switzerland, and there is a growing need for information about the cost and the quality of 
care to be made more widely available. There is also a need for performance measurement 
systems for ambulatory care in this country. In Taiwan, the total ambulatory care was a cost 
driver in the health care system, with expenditure amounting to 66% of the total medical 
expenses. In the same year, inpatient care cost the country 34% of total medical expenses 
(Yeh et al. 2005). 
In a study in the US performed by Amal et al. (2010) increasing co-payments for ambulatory 
care reduced the use of outpatient care among elderly patients in managed-care plans. 
However, this decline was offset by an increase in hospitalisations. These expensive 
hospitalisations were particularly prevalent among those with chronic diseases. Increasing co-
payments for ambulatory care among elderly patients may therefore be seen to have negative 
health consequences and may increase spending for health care (Amal et al. 2010). 
Ambulatory or outpatient care is therefore an important part of the health care provision 
chain, as it is more advanced than primary care, but it can still screen and prevent or 
recommend patients being admitted to hospital for inpatient care. Cost of ambulatory care, 
however, seems to be high in the instances mentioned. 
Harris et al. (2011) state that in South Africa, primary health care is mostly utilised by lower 
income and education groups, while the rich are three times more likely to use private 
hospitals and private ambulatory care like GPs and dentists. Peltzer (2009) agree that primary 
health care is the most frequently used system in SA and mention that, in many areas of 
South Africa, the primary health care (PHC) facilities are the only available or easily 
accessible health service for local communities. PHC services are therefore often 
overburdened. 
2.7.3 Hospital care 
According to Chen et al. (2010), high and growing hospital costs are a reality. When 
comparing hospital costs in the private and public sector using Council for Medical Schemes 
(CMS) data, Schussler (2009) found that the total cost per admission into private hospitals 
increased by 22.1% from 2001 to 2006, and the total cost per admission into public hospitals 
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from 2001 to 2006 increased even more, by 57.7%. Hospital costs, however, are just one of 
the components of health care that have increased over the past years in South Africa.  
Schussler (2009) discusses changes in health care costs when compared to Consumer Price 
Inflation (CPI) and found that, when comparing price increases from 2000 to April 2008, 
medical schemes had the highest increase (158% to CPI), followed by doctors (which 
includes nursing fees) at 137% over the total period. Optician fees increased by 87% and 
private hospital inflation were 74%. Overall Consumer Price Index (CPIX) was relatively 
lower at 64%, whilst public hospitals inflation was only 13%. 
Litvak & Bisognano (2011) found that the new Affordable Care Act in the US will likely 
have the net effect of a large influx of new patients who have health insurance, including 
many who are likely to be older and sicker than current patients. At the same time, hospitals 
may face greater financial pressure than ever before. They further proposed that US hospitals 
will need to become more efficient in order to lower costs, and the activities suggested to 
achieve this include (Litvak & Bisognano 2011): 
• Reducing patient length of stay (LOS) 
• Expanding hospital capacity 
• Expanding staff 
• Increasing bed occupancy 
Chang et al. (2004) describe several input factors that were taken into consideration when 
determining the quality of hospital care in Taiwan: 
a. Number of patient beds (including general beds, special treatment beds, psychiatric beds, 
chronic beds, tuberculosis beds and leprosy beds) 
b. Number of doctors and physicians 
c. Number of nurses (including registered professional nurses and registered nurses) 
d. Number of medical support personnel (including pharmacists, assistant pharmacists, 
medical technologists, medical technicians, medical radiological technologists, midwives and 
dieticians) 
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The three outputs considered were: 
a. Number of patient days which include general care, acute and intensive care, and chronic 
care patient days 
b. Number of ambulatory and emergency clinic visits 
c. Number of patients receiving surgery 
2.7.4 Pharmaceutical care 
Allemann et al. (2013) define pharmaceutical care as “the pharmacist’s contribution to the 
care of individuals in order to optimize medicines use and improve health outcomes”. 
According to Björkman et al. (2008), pharmaceutical care is a worldwide movement among 
pharmacists. The term presents new ideas about how to take care of patients’ medication 
related needs and has stimulated pharmacists to develop the pharmaceutical profession. 
The philosophy of pharmaceutical care encourages pharmacists to practice beyond ensuring 
that patients receive the right drug in the right dose in the right form at the right time. 
Pharmacists should now also see to it that medication-related health outcomes are optimized 
(Allemann et al 2013). 
According to the American Society of Hospital Pharmacists (ASHP 1993), the mission of the 
pharmacist is to provide pharmaceutical care. Pharmaceutical care is defined as “the direct, 
responsible provision of medication-related care for the purpose of achieving definite 
outcomes that improve a patient’s quality of life”. 
The ASHP (1993) also lists the following outcomes to be achieved by pharmaceutical care: 
• Cure of a patient’s disease 
• Elimination or reduction of a patient’s symptomatology 
• Arresting or slowing of a disease process 
• Prevention of a disease or symptomatology 
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2.8 NATIONAL DRUG POLICY 
An access to essential medicines is an essential component of a health system. In relation to 
provision of healthcare services the South African government established National Drug 
Policy to promote accessibility, availability and affordability of essential medicines that are 
safe and effective (DoH 1996).  
 The establishment of the National Drug Policy among other aspects deals with the following: 
It covers a wide range of how pharmaceutical services will be managed within the country. 
For example it includes, monitoring of prices, licensing of premises and professionals, and 
who should handle and dispense medicines. Increase availability of essential medicines in the 
public sector as well as the private sector. Improve quality of care to patients with a 
consequent impact on health outcomes (DoH 1996).  
National Drug Policy was established with the following objectives to deliver its mandate for 
the benefit of the citizens of South Africa. Table 2.3 
Table 2.3 Objectives of the National Drug Policy (DoH 1996) 
Objective  Expected outcome  
Health objectives To ensure the safety, efficacy and quality of drugs 
To ensure good dispensing and prescribing practices 
To promote the rational use of drugs by prescribers, 
dispensers and patients through provision of the 
necessary training, education and information 
To promote the concept of individual responsibility for 
health, preventive care and informed decision making. 
Economic objectives To lower the cost of drugs in both the private and 
public sectors 
To promote the cost-effective and rational use of drugs 
To establish a complementary partnership between 
Government bodies and private providers in the 
pharmaceutical sector 
To optimize the use of scarce resources through 
cooperation with international and regional agencies 
National development objectives To improve the knowledge, efficiency and 
management skills of pharmaceutical personnel 
To re-orientate medical, paramedical and 
pharmaceutical education towards the principles 
underlying the National Drug Policy 
To support the development of the local 
pharmaceutical industry and the local production of 
essential drugs 
To promote the acquisition, documentation and 
sharing of knowledge and experience through the 
establishment of advisory groups in rational drug use, 
pharmacoeconomics and other areas of the 
pharmaceutical sector 
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2.9 SUMMARY OF THE CHAPTER  
Rational use of medicines is defined by WHO as “patients receive medications appropriate to 
their clinical needs, in doses that meet their individual requirements” (WHO 1985). It is 
estimated that half of all medicines globally are inappropriately prescribed, dispensed or sold 
(Hogerzeil 1995). Failure to prescribe in accordance with clinical guidelines is one of the 
common causes of irrational use of medicines. Lack of access to medicines as well as 
inappropriate doses result in serious morbidity and mortality in chronic diseases such as 
diabetes (WHO 2002).  
Globally as well as on a local level attempts have been made to reduce the burden of non-
communicable disease on health care systems as well as improve patient outcomes. In the 
Western Cape province of South Africa the health department has made it a goal to improve 
health outcomes of chronic diseases, like diabetes. In the context of the discussed policy 
documents, frameworks and goals, this study aims to provide evidence on prescribing and 
therapy monitoring practices of diabetes mellitus patients in public primary health care 
facilities. These data should be useful in identifying the current use of glycated haemoglobin 
and fasting plasma glucose and its correlation with evidence-based guidelines.  
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CHAPTER 3: DIABETES MELLITUS  
3.1 OVERVIEW OF THE CHAPTER 
In Chapter 3, diabetes mellitus is discussed, with reference to pathogenesis and classification, 
pathophysiology and natural history, clinical presentation which includes treatment goals, 
pharmacological treatment, treatment monitoring and adjustments, and, complications are 
discussed.    
3.2 INTRODUCTION 
Diabetes mellitus (DM) is one of the most prevalent chronic diseases globally, and continues 
to increase in number and significance (Wetzler & Snyder 2000). Diabetes is defined as a 
group of metabolic disorders that are characterised by hyperglycaemia which result from 
defects in insulin secretion, insulin action or both. DM is categorised into four types on the 
basis of aetiology and clinical presentation: type l diabetes, type 2 diabetes, gestational 
diabetes and other types of diabetes from other causes (Sicree, Shaw & Zimmet 2012). 
The World Health Organisation (WHO) stated that in 1995 DM was already estimated to 
have affected 135 million people globally (WHO 2010). In Africa 7.8 million people in 1997 
were also reported to have been affected by DM (Molleutze & Levitt 2005). Danaei et al 
(2011), have reported that 347 million people were affected by DM in 2008 globally, with an 
estimate that the number will increase to 366 million people in 2030 (WHO 2010). WHO 
(2010) further stated that in 2000, 814 000 people were affected by DM in South Africa (SA) 
and this number is expected to increase to 1-1.5 million people in 2030 (WHO 2010). 
Currently the prevalence of DM in SA is estimated at 9.0% in adults aged 30 years and older 
(Bertram et al. 2013), with the prevalence of 4.2% in female and 2.7% in males in the 
Western Cape in 2005 (Molleutze & Levitt 2005).    
Type 2 DM (T2DM) make up 85 to 95% of all diabetes types in high income countries and 
constitutes even higher percentages in low and middle income countries (Sicree et al. 2012). 
The prevalence of T2DM is increasing rapidly worldwide. As such, T2DM is a common 
serious global health problem which have evolved in many countries along with rapid 
cultural and social changes such as, increasing urbanization, ageing populations, dietary 
changes, reduced physical activity, obesity and other unhealthy lifestyle-associated 
behavioural patterns (Sicree et al. 2012; Igbojiaku et al. 2013).  
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T2DM is classified as a chronic metabolic disorder characterised by progressive worsening 
hyperinsulinaemia and insulin resistance which if left untreated or managed poorly leads to 
high morbidity and mortality from microvascular and macrovascular complications (Chan, 
Abrahamson 2003). Alternatively, proper management of diabetes with appropriate drug and 
lifestyle interventions have yielded improved glycaemic control and a substantial decrease in 
morbidity associated with complications and mortality (Nathan et al. 2009a). The primary 
therapeutic goal for T2DM thus necessitate tight  glucose control set at an individualised 
target, based on patient  age, risk factors and complications (Wetzler, Snyder 2000). A useful 
monitoring tool for glucose control is glycated haemoglobin, also abbreviated as HbA1c 
(Nathan et al. 2005).  
3.3 PATHOGENESIS OF DIABETES MELLITUS AND CLASSIFICATION OF 
DIABETES MELLITUS 
 Diabetes mellitus is defined by the American Diabetes Association (2010) as “a group of 
metabolic diseases characterised by hyperglycaemia, resulting from defects in insulin 
secretion, insulin action, or both”. Diabetes mellitus can be classified into four different 
types, (American Diabetes Association 2010) which are described in Table 3.1. 
Table 3.1 Classification of diabetes mellitus 
Type  Description 
Type 1: 
Insulin-dependent 
diabetes 
It occurs when there is an insulin deficiency 
(complete or severe), associated with the 
autoimmune destruction of beta β-cells 
of the pancreas (Triplitt 2011). 
Type 2: 
Non-insulin dependent 
diabetes 
This type is described as a combination of 
“absent or inadequate pancreatic insulin 
secretion”, together with “tissue resistance to 
the action of insulin’’(Triplitt et al. 2014) 
Type 3: 
Other specific types of 
diabetes 
This type of diabetes may occur as a result of genetic 
syndromes, pancreatic disorders and drugs (Mbanya & 
Ramiaya 2006). 
Type 4: 
Gestational diabetes 
This condition is described as either the initial 
development or the detection of glucose intolerance 
during pregnancy (Mbanya & Ramiaya 2006). 
Glucose intolerance may develop during pregnancy 
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Type  Description 
because of the high levels of anti-insulin hormones 
that are released from the placenta, especially during 
the third trimester. Most often, glucose tolerance 
normalises after six weeks, but in some patients, it 
may continue and manifest as type 2 DM (Mbanya & 
Ramiaya  2006). 
 
Type 1 and Type 2 DM are the major classifications of diabetes conditions that are 
encountered in Sub-Saharan Africa (Mbanya & Ramiaya 2006). There are specific 
characteristics which differentiate these two types of DM.  For the purpose of this thesis the 
focus will be on Type 2 DM.  
3.4 AETIOLOGY AND NATURAL HISTORY OF TYPE 2 DIABETES MELLITUS 
Insulin resistance and an insufficient insulin secretion response are considered to be the 
causes of type 2 DM. However, the specific aetiologies of insulin resistance and secretion in 
type 2 DM are relatively unknown (Mbanya & Ramiaya 2006). The cells in the liver, skeletal 
muscles and adipose/fat tissue become less sensitive to insulin and ultimately become insulin 
resistant (Hawkins et al. 2002: Alberti, Zimmet & Shaw 2006). When insulin resistance 
occurs, glucose can no longer be absorbed in the cells, since insulin is the hormone that 
enables glucose absorption (Hawkins et al. 2002, Alberti et al 2006). The glucose molecules 
remain in the blood stream, which prompts the pancreas to produce more insulin in order to 
compensate for insulin resistance and absorb the glucose molecules (Alberti et al. 2006). The 
constant demand for more insulin production eventually puts a lot of pressure on the β cells 
of the pancreas and ultimately leading to their decreased functioning (Alberti et al. 2006). 
When the β cells are no longer able to produce insulin, the person becomes hyperglycaemic 
characterised by an increased plasma glucose levels. At this stage, the patient is diagnosed 
with type 2 DM (Hawkins et al. 2002, Alberti et al 2006). 
Urbanisation and changes in lifestyle associated with economic developments that have been 
observed in Africa are similar to international trends (Dalal et al. 2011). In Sub-Saharan 
Africa people migrated from rural environments to urban areas, this was inevitably associated 
with a shift in lifestyle from a relatively healthy traditional pattern, to the urban scenario of a 
western diet high in saturated fat and low in fresh fruit and vegetables (Gill et al. 2009). Low 
levels of exercise, smoking, increased alcohol intake and urbanisation are the major factors 
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leading to the development of type 2 DM. This rapid epidemiological transition is driving the 
emergence of high and increasing prevalence rates of type 2 DM in South Africa (Bertram et 
al. 2013).  
3.5 COMPLICATIONS   
The ADA (2014) reports that there is “long-term damage, dysfunction and failure of different 
organs; especially the eyes, kidneys, nerves, heart and blood vessels”, linked to the 
chronically increased blood glucose levels evident in diabetics. These complications form 
part of the major factors accounting for the increased morbidity and mortality rates on a 
global level; and they may be broadly classified into the following two categories: 
macrovascular and microvascular (ADA 2014). As the names describe, macrovascular 
complications involve the large arteries, whereas microvascular complications include those 
affecting the smaller blood vessels and capillaries (Triplitt et al.2014). Table 3.2 contrasts 
examples of the two different types of complications of DM. 
Table 3.2 Macrovascular and microvascular complications of diabetes mellitus. 
MACROVASCULAR COMPLICATIONS MICROVASCULAR 
COMPLICATIONS 
Stroke Amputation 
Angina Autonomic Neuropathy 
Myocardial Infarction Diabetic Retinopathy 
Peripheral Vascular Disease End-stage renal disease 
Cardiac Failure Erectile Dysfunction 
Transient Ischaemic Heart Attack Micro-/Macro-albuminuria 
 Osteomyelitis 
 Peripheral Neuropathy 
Adopted from SEMDSA 2012 & ADA 2014 
In 2006, Mbanya and Ramiaya reported on studies performed on the South African 
prevalence of diabetes complications. In a study performed by Gill, Huddle and Rolfe in 1995 
in a secondary care clinic, 42% of 64 patients were found to suffer from neuropathy. In 
another study performed by Bawa, Bradshaw, Levitt, Maphumolo and Zwarenstein in 1997, 
37% of 300 patients in a primary care clinic, were reported to have suffered from 
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nephropathy. In 1997, in a study conducted by Becker, Joannou, Kalk, Mahanlal, Mahomed 
and Ntsepo, retinopathy was found to be prevalent amongst 37% of the 507 patients who 
were attending a secondary care clinic. 
3.6  TREATMENT  
3.6.1 Treatment goals 
Goals of therapy in diabetes mellitus are to control blood sugar level, achieve and maintain 
HbA1c values below the patient’s individualised target levels prevent acute complications of 
glycaemia and manage chronic conditions associated with diabetes, e.g hypertension and 
dyslipidaemia. Also prevention and treatment of microvascular and macrovascular 
complications of diabetes (Department of Health (DoH) 2008; SEMDSA 2012)   
3.6.2 Drugs  
The pharmacological management of T2DM entails the use of oral hypoglycaemic agents and 
insulin, either as monotherapy, or in combination. The hypoglycaemic agents that are 
available in the public sector are; metformin, sulfonylurea derivatives e.g gliclazide, 
glimepiride and glibenclamide and insulin (DoH 2008; DoH 2012). The oral hypoglycaemic 
agents are categorised according to their different mechanisms of action. Table 3.3 
summarises all the different types of oral hypoglycaemic agents in terms of their mechanisms 
of action, mean lowering of HbA1c, therapeutic considerations and disadvantages.     
Table 3.3 Anti-diabetic medications used in the management of T2DM adopted from 
SEMDSA (2012)  
Class  Drug  Mean 
lowering of 
HbA1c 
Therapeutic 
considerations 
Disadvantages  
Alpha-
glucosidase 
inhibitors   
Acarbose  <1% Weight neutral as 
monotherapy, targets 
postprandial 
hyperglycaemia 
Gastrointestinal effects, 
needs frequent doses 
Biguanides  Metformin  1-2% First line drug in 
obesity, reduces 
cardiovascular events 
and mortality 
Gastrointestinal 
side-effects.  
Incretins  Dipeptidyl peptidase-4 inhibitors: 
linagliptin, saxagliptin, sitaqliptin, 
and vildagliptin   
<1% Weight neutral, 
improves 
postprandial 
hyperglycaemia 
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Class  Drug  Mean 
lowering of 
HbA1c 
Therapeutic 
considerations 
Disadvantages  
 Glucagon-like peptide agonists:  
Exenatide and Luraglutide  
1-2% Causes weight loss, 
possible potential for 
improved beta cell 
function 
 
Insulin 
secretagogues  
Sulphonylureas: 
Glibenclamide, Gliclazide, 
Glimepiride and Glipizide 
 
 
 
 
 
Meglitinides: 
Nateglinide  
Repaglinide  
1-2% 
 
 
 
 
 
 
 
1% 
1-2% 
Well tolerated, 
relatively rapid 
glucose-lowering 
response. 
 
 
 
 
Associated with less 
hypoglycaemia than 
sulphonylureas  
Hypoglycaemia relatively 
common but variable, 
glibenclamide can cause 
severe hypoglycaemia and 
weight gain. 
 
Causes hypoglycaemia and 
weight gain. 
Insulin  Rapid-acting analogues 
Short-acting regular 
Intermediate-acting 
Long-acting basal analogues 
Pre-mixed human 
Pre-mixed analogue    
˃2% Potentially greatest 
HbA1c reduction and 
no maximal doses, 
numerous 
formulations and 
delivery systems 
allow for regimen 
flexibility. 
Significant risk of 
hypoglycaemia. 
Increased risk of weight 
gain. 
 
 
3.6.3 Treatment monitoring 
Glycaemic control and frequent monitoring are essential in the management of diabetes (Del 
Prato et al 2005). Diabetic Control and Complications Trial (DCCT), United Kingdom 
Prospective Diabetes study (UKPDS) and Action in Diabetes and Vascular Disease: Preterex 
and Diamicron Modified-Release Controlled Evaluation (ADVANCE) have shown in their 
studies that there is a correlation between glycated haemoglobin, glucose level and the risk of 
the development of both macrovascular and microvascular complications (Patel et al. 2008; 
Igbojiaku et al 2013). Glycated haemoglobin (HbA1c) is a measure that reflects both fasting 
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and postprandial glucose concentrations over a 3 month period (Sherifali et al. 2010) and is 
therefore an immportant indicator for assessing the quality of diabetes care in patients (Zhang 
et al. 2000).  Nathan et al. 2008, further highlighted that HbA1c is thus used as a gold 
standard in assessing chronic glycemia.     
In a nine-year follow-up study involving 4662 men and 5570 women, Khaw (2003) 
demonstrated that a 1% rise in the level of HbA1c was associated with an increased risk of 
death of up to 28% and 24% in women and men respectively. Alternatively, Tkac (2009) and 
Del Prato et al. 2005 have highlighted that findings from the UKPDS study, have revealed 
that a decrease in HbA1c resulted with a decreased chances of myocardial infarction by 14%. 
While Zhang et al 2000, have found that HbA1c of >9.5% was a risk factor for the 
progression and poor life in individuals with diabetes.     
The American Association of Clinical Endocrinologists (AACE) (2007) issued guidelines 
that placed emphasis on the importance of achieving and maintaining glycaemic levels as 
close as possible to the normal non-diabetic level (American Association of Clinical 
Endocrinologists 2007). These recommendations are based on the findings from 
epidemiological studies mentioned earlier. Many countries have developed management 
guidelines with specified glycaemic targets in order to manage and monitor these chronic 
conditions as illustrated in Table 3.4.  
Table 3.4 General glycaemic targets for the care of patients with diabetes as 
recommended by various organizations and Department of Health (2008) primary 
health care guidelines.  
Organization HbA1c (%) Fasting Plasma 
Glucose (mmol/L) 
Postprandial glucose 
(mmol/L) 
DoH (2008) (Primary health care) <7 4-6 4-8 
 SEMDSA (2012) <7 4-6 4-8  
 American Diabetes Association (2014) <7 3.9-7.1 <10  
American Association of Clinical Endocrinology 
(2007) 
≤6.5 <6.0 <7.8  
International Diabetes Federation-Europe (IDFE) 
( 2007) 
≤6.5 ≤6.0 ≤7.5  
National Institute for health and Clinical Excellence 
(NICE) 2014 
≤6.5 <6 <7.0 
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However, HbA1c differs from other monitoring parameters in that it must be individualised, 
because it is influenced by age, race/ethnicity, type and duration of diabetes, comorbidities 
and patient adherence (Zhang et al. 2000).As illustrated in Table 3.5. 
Table 3.5 Individualised targets for glycated haemoglobin, fasting plasma glucose and 
postprandial glucose (SEMDSA 2012) 
Patient type Target HbA1c Target FPG Target PPG 
Young, stable patient at 
individualised targets, this patient 
is at low risk of developing 
complications. Newly diagnosed 
No cardiovascular disease 
<6.5% 4.0-7.0mmol/L 4.4-7.8mmol/L 
Majority of patients <7% 4.0-7.0mmol/L 5.0-10.0mmol/L 
Elderly patient unstable at 
individualised targets and the body 
fails to recognise episodes of 
hypoglycaemia due to lack of 
symptoms. This patient is at high 
risk of developing cardiovascular 
complications due to 
hypoglycaemia. 
 
<7.5% 4.0-7.0mmol/L <12.0mmol/L 
 
The Society for Endocrinology, Metabolism and Diabetes of South Africa have indicated a 
strong epidemiological evidence that HbA1c levels ˃7.5% in T2DM have a 2.5-5 fold greater 
relative risk of developing microvascular complications, and a 5 fold greater risk of 
developing peripheral artery disease (SEMDSA 2012).  
Regular monitoring and appropriate response to abnormal results have been shown to reduce 
complications such as myocardial infarction, cerebrovascular accidents and retinopathy in 
diabetic patients (Igbojiaku et al. 2013). Current South African guidelines for primary health 
care indicate that all people with diabetes should have their HbA1c repeated either  every 3-6 
monthly for those with therapy adjustments or  HbA1c levels above target, or  annually for 
those with HbA1c levels at target and no therapy adjustments Table 3.6 (DoH 2012). 
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Table 3.6 Diabetes monitoring tests and frequencies (DoH 2008) 
Test  Frequency  
HbA1c Every 3-6 monthly if treatment changes or goals not 
met. Annually monthly if stable.  
Fasting plasma glucose test Every routine diabetes visit  
Postprandial glucose test Every routine diabetes visit 
Random glucose test  Every routine diabetes visit 
Blood pressure Every routine diabetes visit 
Serum potassium  Annually  
Serum creatinine  Annually 
Waist circumference  Every routine diabetes visit 
Comprehensive foot examination  Every routine diabetes visit,  
Fundoscopy  Annually 
Proteinurea  Every routine diabetes visit 
BMI Every routine diabetes visit 
Lipids profile Annually 
3.7 ADJUSTING TREATMENT 
Diabetes treatment is adjusted based on HbA1c results (Nathan et al. 2008). Results from the 
UKPDS 33 shows that from the newly diagnosed type 2 diabetes patients treated with the 
intensive glycemic control with sulphonylureas or insulin obtained a median HbA1c of 7.0% 
during a 10-year follow-up while patients in the conventional group (managed with lifestyle 
modification) obtained a median HbA1c of 7.4% (Tkác 2009). A significant risk reduction of 
12% in the incidence of any diabetes related endpoint in the intensive group was observed. 
The diabetes-related death and all-cause mortality were both not significantly reduced by 
10% and 16% respectively (Tkac 2009). 
Tkac (2009), and MacIsaac & Jerums (2011) have highlighted that in UKPDS 34 of 1704 
overweight patients with type 2 diabetes were randomised to intensive treatment by 
metformin, sulphonylurea/insulin or to conventional treatment. Patients treated by intensive 
metformin treatment had median HbA1c level of 7.4% during the follow-up, while patients in 
the conventional group had median HbA1c level of 8.0%. Patients allocated to metformin 
when compared to the conventional group had significantly reduced risk for diabetes related 
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end point by 32%, for diabetes death by 42%, for all-cause mortality by 36% and for 
fatal/non-fatal myocardial infarction by 39% (MacIsaac & Jerums 2011). Holman et al.(2008) 
further indicated that in the same study, patients allocated to metformin when compared to 
patients allocated to insulin/sulphonylurea had lower risk for any diabetes related endpoint, 
for all-cause mortality and for stroke. In the Action to Control Cardiovascular Risk in 
Diabetes (ACCORD) trial 10251 patients with mean age 62years and median duration of 10 
in diabetes were randomly selected and assigned to intensive glucose-lowering treatment with 
a target of HbA1c <6% or to a standard diabetes treatment targeting HbA1c level in the 7.0-
7.9% (Tkac 2009). There was no specific treatment in either group (Holman et al 2008). The 
intensive group obtained a median HbA1c of 6.4% while the standard group obtained a 
median 7.5% (Holman et al 2008).  
The study was terminated after 3.5 years of follow-up in 2008 because of observed 22% 
significant increase in all-cause mortality and 35% increase in cardiovascular mortality in 
patients with intensive glycemic control (Tkac 2009). The primary end point of the study was 
non-significantly reduced in the intensive treatment group by 10%. While significant 
reduction in the incidence of nonfatal myocardial infarction by 24% was observed in the 
intensive therapy group. The analysis from this group revealed a significantly more beneficial 
effect on primary endpoint reduction in the intensive treatment group in patients without 
previous cardiovascular disease with diabetes control of HbA1c of 8.4% (Tkac 2009).                 
  
In the ADVANCE study, 11140 patients with mean age 66years and mean diabetes duration 
of 8 years were randomly assigned to intensive treatment with the use of gliclazide modified 
release and other drugs with a target of HbA1c <6.5% or standard treatment(Holman et al 
2008). The median follow-up of patients was 5years. The primary endpoint of combined 
major macrovascular and microvascular events was reduced significantly by 10% in the 
intensive treatment group. 6% reduction in the incidence of macrovascular events was 
observed. In comparison to ACCORD trial no significant increase in all-cause mortality was 
observed. The most pronounced effect in this study was a 21% reduction of the development 
of new or worsening nephropathy (Tkac 2009). 
In the Veterans Affairs Diabetes Trial (VADT) , 1791 patients with mean age of 60 years and 
mean diabetes duration of 11.5 years were randomly assigned to intensive diabetes treatment 
aiming for HbA1c <6% and standard treatment group aiming for HbA1c<9% (Duckworth et 
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al. 2011). The goal for HbA1c between group differences was 1.5%. The intensive group had 
median on-treatment HbA1c was 6.9% and 8.4% for the standard group. The primary 
endpoint was any major cardiovascular event. After the median follow-up of 5.6 years, there 
was observed a non-significant reduction of primary endpoint in the intensive treatment 
group by 12%. Patients treated with intensive regimen had reductions in worsening 
albuminuria by 38% with borderline significance (Tkac 2009). 
The Prospective Pioglitazone Clinical Trial in Macrovacular Events (PROactive) study 
consisted of 5238 patient with developed macrovascular diseases. The interventional study 
group patients were given pioglitazone in addition to the previous treatment (Tkac 2009; 
Aguilar 2011). The treatment resulted in on-study difference of HbA1c level by 0.6% 
between the treatment groups. The patients on pioglitazone had non-significantly reduced the 
incidence of widely defined primary endpoint by 10%. The incidence of secondary endpoint 
(total mortality, non-fatal myocardial infarction and stroke) which was not predefined in the 
study design significantly reduced by 16% in the pioglitazone treatment patients (Tkac 2009; 
Aguilar 2011). In patients with previous stroke, pioglitazone treatment reduced fatal and non-
fatal stroke by 47% and in patient with previous myocardial infarction pioglitazone reduced 
fatal and non-fatal myocardial infarction by 28% (Tkac 2009). The results of these 
epidemiological studies leads to an individualisation of diabetes control goals (table 3.5). 
According to SEMDSA the  general goal of HbA1c<7% should be maintained, but for certain 
groups of patients more stringent goal must be recommended based on the subgroup analysis 
of the mentioned studies (SEMDSA 2012).     
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Figure 3.1 Step wise approach in the management of T2DM to reach individualised 
glycaemic targets (SEMDSA 2012) 
Following lifestyle modification, a stratified selection of therapy is suggested based on the 
level of HbA1c (HbA1c 6.5%– 7% monotherapy, HbA1c ˃7% after three months on 
treatment dual therapy, and HbA1c ˃7.0% after another three months or above individualized 
target combination dual/triple and/or insulin therapy) (SEMDSA 2012). Choice of therapy is 
also made based on the risks of weight gain and hypoglycemia, the potential benefits with 
regard to CV risk and lipid profile, and correction of hyperglycemia (Aguilar 2011). Use of 
insulin and sulphonylureas, as reported in the UKPDS, were associated with weight gain, and 
these agents provided no benefit with regard to blood pressure, lipids, or cardiovascular risk 
(Aguilar 2011). Evidence from epidemiological studies supports the idea that complete care 
for patients with T2DM requires treatment of all cardiovascular risk factors. However, long-
term follow-up of large clinical trials, including the UKPDS, indicated that treatment to 
HbA1c of 7.0% in the years close to diabetes diagnosis may be associated with improvement 
of long-term cardiovascula risk (Nathan et al. 2009b). Ten-year follow-up of obese patients 
with T2DM treated in UKPDS with metformin revealed sustained benefit of intensive therapy 
with regard to risk reduction for any diabetes-related end point, myocardial infarction, and 
death from any cause despite integration of HbA1c after the first year(Aguilar 2011). Thus, a 
lower HbA1c may be a good target for younger patients with a shorter duration of T2DM and 
those with no history of cardiovascular disease where one hopes to prevent coronary heart 
 
 
Step 3 if HbA1c ˃7% after three months or remains above individualised target 
 Metformin and Sulphonylurea  Basal insulin 
 
Step 2 if HbA1c˃7% after three months or above individualised target  
 Metformin   Sulphonylurea 
 
Step 1 at diagnosis 
 Lifestyle modification   Metformin   
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disease/cardiovascular disease events, whereas a less intensive goal may be appropriate for 
older patients with a longer history of T2DM and evidence of coronary heart disease (Aguilar 
2011). 
3.8 SUMMARY OF THE CHAPTER 
This chapter discussed Pathogenesis and classification of DM. A brief overview of the 
aetiology and natural history of T2DM were discussed. Epidemiology, mortality and cost 
implications of diabetes were also highlighted. The clinical presentation treatment goals, anti-
diabetics and their mean lowering of glycated haemoglobin were highlighted. Treatment 
monitoring and adjustments in therapy were thoroughly discussed. The chapter was then 
concluded by a discussion of diabetes complications and their impact in South Africa. 
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CHAPTER 4: METHODOLOGY 
4.1 INTRODUCTION  
In this chapter the research methodology is discussed. Followed by research design, selection 
and composition of the study population, study variables, and statistical analysis of the data 
are discussed. The reliability and validity of the research instruments are also discussed, and 
finally a chapter summary is given. 
4.2 RESEARCH METHODOLOGY 
4.2.1 The literature review  
The literature search was conducted as follow: 
Electronic databases: Google Scholar, PubMed, Medline, Science Direct, Cochrane library 
and Archives. Electronic Journals:  European Heart Journal, Journal of American Diabetes 
Association, Journal of Endocrinology, Metabolism and Diabetes of South Africa, etc. Text 
books, Acts and Regulations. Government publications and chronic disease management 
guidelines from Department of Health Western Cape were also used.  
Search terms: Type 2 diabetes mellitus (T2DM), glycaemic monitoring indicators, Diabetes 
management guidelines 
4.2.2 Research Design 
This study is descriptive, retrospective and quantitative in nature. Descriptive studies can be 
used for the purposes of observing, documenting and describing situations of naturally 
occurring aspects of a certain theory to serve as a starting point for hypothesis generation. For 
example, the natural history of disease is essential to judging the effect of therapeutic 
interventions (Polit & Beck 2004). Polit & Beck (2004) defines retrospective designs as 
designs in which a phenomenon existing in the present is linked to a phenomenon that 
occurred in the past, before the study was initiated. This means the researcher is interested in 
a present outcome and tries to determine factors that caused it. This study can be considered 
quantitative, as data were statistically analysed and compared in order to make certain 
assumptions and conclusions. 
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4.3 SELECTION AND COMPOSITION OF STUDY POPULATION 
4.3.1 Study setting 
The population of the Western Cape is estimated to be 5.3 million people and represents 
approximately 10,45% of the total national population (Western Cape Destination Fact 
Sheet:2013). The coloured demographic group represents 50% of the total population of the 
Western Cape, followed by the Black 30.1%, White 18.4% and Indian/Asian 1.3% (Western 
Cape Destination Fact Sheet:2013). The Cape Metropole constitutes 64.2% of the total 
population of the Western Cape (Regional Development Profile City of Cape Town: 2012). It 
is further divided into 8 health sub-districts. The study was conducted in the Tygerberg 
region of the Cape Town Metropole. The Tygerberg health district is situated central in the 
Metropolitan as shown in Figure 1. Tygerberg covers approximately 11985 hectare (City of 
Cape Town: Tygerberg Health District 2013). The population size was estimated at 597732 in 
2011, with the coloured ethnic group being the most predominant (66%) in the area. Black 
Africans constitute 19.3%, whites 10.8% and Indians/Asians 1.4% (City of Cape Town: 
Tygerberg Health District 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
39 
 
 
Figure 4.1 Map of the Cape Town Metropole indicating 8 sub-districts, this study was 
done in the Tygerberg sub- district.  
Community health centres (CHC) at the primary health care level of the public sector 
healthcare system are involved with the chronic management of diabetic patients. After initial 
diagnosis and stabilisation at primary health care level patients are referred to an appropriate 
level of care. The levels of care include community-based, primary health care or hospital 
level, which correlates to the stratification categories of chronic patients which include stable, 
‘at risk’ and decompensated, respectively (Table 4.1).  
These levels have been assigned to streamline clinical management. According to protocol, 
the stable group is those patients who are controlled at their individualized HbA1c and blood 
pressure levels. These patients are decanted to the community level of care which means that 
they receive a 6 month repeat prescription from the clinical nurse practitioner or medical 
officer at their CHC, which is sent to the chronic distribution unit (CDU). Every two months 
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patients come to collect their medication either at a pick up point which may be at the CHC 
or at community diabetes club. A register for all the club members is kept at the diabetes club 
for scheduling of appointments and also sent to the CDU. Once the six-monthly prescription 
runs out, patients are reviewed by the clinical nurse practitioner or medical officer at the PHC 
facility for re-categorisation. The ‘at risk’ group are those who require more frequent review 
at the out-patient department of a CHC by the medical officer or family physician on a 
monthly basis in order to optimise management interventions and patient support structures to 
prevent progression of the disease into complications. The decompensated group are those 
who require same day referral to the hospital due to diabetic ketoacidosis, pregnancy or 
patients less than 30 years of age. They are either acutely decompensated or those who need 
specialist care. 
Table 4.1 Chronic disease stratification table for diabetes mellitus used at community 
health centres in the Western Cape Province (Western Cape Government: Health 2012) 
Criteria for 
stratification 
Gold standard  Community 
Based 
Service: 
Stable 
Primary Health 
Care: At risk 
Hospital: Decompensated 
 Acute Specialist 
Glycemic 
control and 
complexity  
Individualised 
HbA1c target 
Low risk: 
≤6.5% 
Majority:  ≤7% 
High risk: ≤7.5-
8.5%  
  
Controlled at 
individualise
d HbA1c 
target of 
≤6.5% 
≤7% 
≤7.5-8.5% 
with hypo-
unawareness 
or poor short 
term 
prognosis 
 
HbA1c above 
individualised 
target 
HbA1c ˃11% 
On anti-diabetic 
medications 
And with 
significant co-
morbidities 
Diabetic 
ketoacidosis 
Poor glycemic 
control despite 
optimal PHC 
management. 
 Pregnancy 
Age <30 years   
 
Blood 
pressure 
control and 
complexity 
Low risk 
diabetic patient 
BP<140/80mm
Hg 
For a high risk 
BP<150/90 
Controlled at 
target 
140/80mmH
g and 
150/90mmH
g 
BP˃180/110mmH
g and patient is on 
several blood 
pressure 
medications 
BP˃180/110mmH
g 
With one of this 
symptoms: 
Headache, 
difficulty in 
breathing, visual 
symptoms, chest 
Intolerance to 
multiple 
antihypertensive
s. 
Suspect 
secondary course 
Poor BP control 
despite optimal 
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Criteria for 
stratification 
Gold standard  Community 
Based 
Service: 
Stable 
Primary Health 
Care: At risk 
Hospital: Decompensated 
 Acute Specialist 
pain, leg swelling 
and confusion  
 
management 
Total 
cholesterol  
<4.5mmol/L <4.5mmol/L >6.5mmol/L on 
statins 
 >7.5mmol/L or 
triglycerides 
>15mmol/L  
despite statins 
4.3.2 Sampling strategy  
The first level of sampling was done using purposive sampling to select the facilities, and this 
was based primarily on the staff complement that manages chronic patients at the facility. It 
included the availability of a family physician, permanent / part-time medical officer and 
clinical nurse practitioner at the facility. This was done in consultation with the pharmacy 
managers and family physicians in the facilities.    
The second level of sampling was done randomly from diabetes club registers so that each 
individual had the probability of being selected and the generalizability of the study results 
can be possible. Patients with T2DM were selected as those treated with oral anti-diabetics 
and insulin. 
4.4 SELECTION CRITERIA 
4.4.1 Inclusion criteria 
The study population comprised of all T2DM patients, older than 18 years of age, who have 
been on anti-diabetics for a minimum of 6 months and categorised as “stable”. Also, they 
were with or without the following co-morbidities: cardiovascular diseases, renal diseases, 
peripheral vascular diseases and ophthalmic complications. 
4.4.2 Exclusion criteria 
All patients younger than 18 years of age, those who have been on treatment for less than 6 
months and categorised as at risk or decompensated, and patients with type 1 diabetes 
mellitus were excluded.   
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4.5 DATA SOURCES 
Patient medical records in the facilities were used as data sources. The folders were selected 
randomly on the diabetes club register as there is no electronic system available. The folder 
contains patient demographics, medical history, laboratory and clinical monitoring 
information, such as anti-diabetic medication regimens, glycaemic monitoring indicators and 
other clinical information such as co-morbidities/complications.   
4.6 DATA COLLECTION 
The principal investigator was responsible to inform facility managers at each facility 
included in the study about the research project.  Confirmation of ethical approval as well as 
proposal documents were given to each facility as soft copies via email and hard copies 
before commencement of the actual data collection. The data collection tool was designed to 
collect an 18 month’s period information for all variables relevant to chronic diabetes 
monitoring as set out by the Department of Health (Appendix 1). Twelve final year pharmacy 
students were trained to assist with data collection and data capturing. The registry personnel 
in the hospital assisted with folder drawing. Data collection was carried out from 11th 
February 2015 to 9th June 2015.  
4.6.1 Validity of measurement tools   
The data collection tool was designed in such a way that it contained all the variables relevant 
to the chronic diabetes monitoring set out by the Department of Health (Western Cape 
Government: Health 2012). 
4.6.2 Pilot study  
The principal investigator piloted the study in one facility to pre-test the data collection tool 
and the data collection process. Findings from the pilot study revealed possible limitations to 
the study, and based on these findings, the tool was modified accordingly. It was found that 
the date of first diagnosis with T2DM was not available in the patient medical records and 
also the social history (diet, exercise, smoking and alcohol) was not included in the routine 
chronic medical check list, hence they were excluded for data collection.   
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4.7 DATA MANAGEMENT AND MEASUREMENT    
Data was captured into an electronic spreadsheet using Microsoft Excel®. After data 
capturing, the data collectors were paired into groups of two and checked for accuracy of 
capturing. One reading from the data collection form while the other reading from the Excel® 
spreadsheet. This was done twice by 2 different pairs and the process was supervised by 
primary researcher. The final spreadsheet was exported into SPSS version 23 for statistical 
analysis. 
Data from the data collection tool was categorised into four sections, as described below.  
Appendix 1 gives detailed information of all variables included.   
Demographics – examined factors as, gender, age, date of birth, race/ethnicity, smoking, 
alcohol use and allergy. 
Diagnoses – it included all the medical history of the patient e.g Type 2 DM and Co-
morbidities. 
Laboratory and clinical monitoring information- it included, HbA1c, fasting plasma 
glucose and blood pressure. 
Medication – it included anti-diabetic medication regimens and medication for co-
morbidities. 
 
4.7.1 Description of variables used in the analysis 
This section describes how data was organised to meet the objectives of the study. Table 4.2 
describes the type of variable, unit of measurement and generation of variable. The variables 
generated to meet objectives are then described. 
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Table 4.2 Description of variables used in the analysis 
Variable  Type  Description  
Gender  Numeric  Male or female  
Age  
(years) 
Categorical  Calculated from South African ID and presented as categories.   
Glycated haemoglobin (HbA1c) 
(%) 
Scale  Three level variable:  low risk (<6.5),                                                                                             
majority (7) and high risk (7.5-8.5). It was analysed to establish 
percentages of participants with results within target values. 
Fasting plasma glucose (FPG) 
(mmol/L) 
Numeric FPG, measurement of glucose level for just few hours. It was 
analysed to establish percentages of participants with results within 
target. The set target for all age groups is <7mmol/L.  
Systolic blood pressure  (SBP) 
(mmHg) 
Numeric  SBP, recorded systolic blood pressure. It was analysed to establish 
percentages of participants who are hypertensive and monitor the 
level of control. With the target of <140mmHg for the majority and 
<150mmHg. 
Diastolic blood pressure (DBP) 
(mmHg) 
Numeric  DBP, recorded diastolic blood pressure. It was analysed to establish 
percentages of participants who are hypertensive and monitor the 
level of control. With the target of <80mmHg and <90mmHg. 
Body mass index (BMI) (kg/m2) Numeric  BMI, calculated from weight in kg/ (height in m)². It was analysed to 
establish nutritional status of participants and find percentages of 
overweight or obese. With the target value of ≤25kg/m². 
Total cholesterol (mmol/L) Numeric  Recorded cholesterol. It was analysed to establish the percentages of 
participants who have dyslipidaemia. With the target value of 
<4.5mmol/L.  
Prescription Numeric  Two level variable: given or not given. Data relating to the anti-
diabetic medication were collected from the last 3 prescriptions 
written for the patient. They were analysed according to anti-diabetic 
drugs prescribed as well as therapy adjustments when compared to 
the previous prescription. Depending on the number of repeats on the 
prescription patient medication were available for a maximum of 18 
months and possible treatment adjustment could have taken place.   
4.8 DATA ANALYSIS 
With the use of both Microsoft Excel® and SPSS version 23, various data analyses were 
performed for the study sample. The prevalence of HbA1c testing, fasting plasma glucose 
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testing, blood pressure testing, and body mass index measurements were analysed. The 
analysis of comorbid disease states, anti-diabetic use and therapy adjustments analysis were 
selected and utilized as measuring instruments for data analysis in order to achieve the 
objectives of the investigation. The results are presented in chapter 5.  
4.8.1 Analysis of the therapeutic management of T2DM  
The number of anti-diabetics prescribed for each patient was evaluated. Anti-diabetics 
referred to all oral anti-diabetics used and insulin. Insulin included all of the insulin 
preparations that were dispensed to patients. Biphasic insulin analogues, biphasic insulins, 
intermediate-to-long acting insulins and long-acting insulins were all categorised as insulin. 
The product name field was used to determine the category distribution of all anti-diabetics 
prescribed in the study. The terms used in the study were: monotherapy, dual therapy and 
triple therapies. Monotherapy referred to metformin or sulfonylurea monotherapy, dual 
therapy referred to metformin and sulfonylurea, metformin and insulin or sulfonylurea and 
insulin, while triple therapy referred to metformin, sulfonylurea and insulin. 
4.8.2 Comorbid disease analyses 
The nature of the comorbid disease states and their management were considered in the 
analysis.  
4.9 STATISTICAL ANALYSIS OF THE DATA 
Microsoft Excel® and SPSS version 23 were used for statistical analysis. Descriptive and 
inferential statistical methods were employed for the analysis. All data set were analysed for 
normality using Shapiro–Wilk test. Normally distributed data were analysed using parametric 
tests. Parametric tests used were one-sample t-test, paired t-test and repeated measures 
ANOVA.     
4.9.1 Descriptive statistics 
To obtain descriptive statistics, frequencies were used for categorical variables where by the 
response was classified into how many males or female were actually in the study or gave the 
response (Pallant 2011). Pallant (2011) describes frequency as the number of occurrences of a 
determinable entity per unit of time or population (Pallant 2011). Later cross tabulation was 
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done to compare the variables in the two groups. These helped to determine the relationship 
between and among the two groups in the same and different variables.  
4.9.2 Inferential statistics 
Inferential statistics were used to test whether the results of the data analysis were due to 
relationships or random factors. They helped to confirm or reject the predictions being tested 
(Field 2009).  Effect size which is the magnitude of the differences between two groups was 
analysed using P value from correlation bivariate analysis with an option of Spearman 
Correlation Coefficient because of the nature of the variables which were mostly ordinal. The 
p-value of an analysis was calculated in order to determine whether a result was statistically 
significant. In essence, statistical significance indicated the degree to which the result being 
analysed were accurate and represented the population. 
When the p-value of an analysis was 0.05 or less it indicated that there was a 95% probability 
that the relation between the variables being assessed in the sample happened by chance 
(Field 2009).  
4.10 RELIABILITY AND VALIDITY OF THE DATA 
The data was verified with respect to age, diagnosis, duration on treatment and clinical 
category. Data collection tools used in this study included all variables relevant to chronic 
diabetes monitoring as set out in the study conducted by the Western Cape Department of 
Health 2012. 
4.11 ETHICAL APPROVAL FOR THE STUDY 
A research proposal was submitted to the University of the Western Cape Ethics Committee 
and approval granted (registration no 14/9/50) for the conduction of the research. An 
approval was obtained from the Western Cape Provincial Health Research Committee 
(reference no 2014RP137, Appendix 2) to gain access to the health facilities and patients 
medical records to be used in the study.  
For confidentiality reasons, before data collection from the patient medical record ensued, a 
unique identifier was assigned to each participant via the patient identification tool (Appendix 
3). The data collection tool only contained the unique identifier. Furthermore, due to the 
retrospective nature of the study, there were no face to face interactions with participants thus 
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no informed consent was taken. At facilities where the study was done information forms 
were provided for the facility managers after the presentation of the study objectives and 
methodology (Appendix 4). 
The study was conducted with the ethical principles of the Declaration of Helsinki (World 
Medical Association. 2013). 
4.12  SUMMERY OF THE CHAPTER 
In this chapter, empirical investigation of the study which included, research design, selection 
and composition of study population, data collection, data management and measurement, 
data and statistical analysis, reliability and validity of the data were discussed.  
In the following chapter analysis on the available data and results of the empirical 
investigation will be discussed. 
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CHAPTER 5: RESULTS 
5.1 INTRODUCTION 
This chapter outlines the results of the empirical investigation. Firstly demographic 
characteristics of the study population are presented, then participant’s glycaemic monitoring 
results are categorised into stable and unstable according to evidence-based management 
guideline targets for glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) levels. 
Finally treatment and treatment adjustments among patients whose glycaemic monitoring 
parameters are within and outside target will be presented.  
5.2 DEMOGRAPHICS OF THE STUDY POPULATION 
Data were collected from 596 patient medical records treated at 5 community health centres 
in the Cape Town Metropolitan region South Africa. Twenty-one participants were excluded 
from data analysis because of the following reasons;  
• Six participants had no oral anti-diabetics only insulin was prescribed therefore it was 
not possible to be certain of a type 2 diabetes mellitus diagnosis. 
• Four participants had only one glycaemic test result   
• Three had only one prescription with no follow-up information 
• Five participants had abnormally low HbA1c results  
• Three participants had no medication information. The demographic characteristics of 
the study population (575) are summarised in Table 5.1. 
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Table 5.1 Demographic information of the study population (n: 575) 
Variable  Number  Mean  ± 
Standard 
deviation 
Minimum -
Maximum 
Target 
range 
Age in years    575 57±11.38 29-92 N/A 
Gender                      N/A 
                                     Male  206 (36%)   N/A 
                                     Female  369 (64%)   N/A 
HbA1C (%)  493 8.78 ± 1.63  5.1-17.1 N/A 
                   Low risk category                         13 8.15 ± 1.63 5.9-12 <6.5% 
                   Majority  category    219 8.80 ± 2.12 5.2-15.2 <7% 
                   High risk  category   261 8.75 ± 2.37 5.1-17.1 <7.5% 
Fasting plasma glucose (mmol/L)    570 10.03 ± 3.62 4.0-21.1 <7 mmol/L 
Systolic blood pressure (mmHg)   562 139.68 ± 21.82  101-217 <140mmHg 
Diastolic blood pressure (mmHg)   562 79.91 ± 11.13 50-116 <80mmHg 
Total cholesterol  (mmol/L)  433 5.19 ±1.25 1.1-9.4 <4.5mmol/L 
Body mass index (kg/m2)     400 31.61 ± 6.16 17.93-56.36 <25kg/m2 
                                  Male  140 30.72 ± 5.71 19.14-50.27 <25kg/m2 
                                  Female    260 32.09 ± 6.35  17.93-56.36 <25kg/m2 
Key: N/A not applicable  
The study comprised both males (36%) and females (64%) with the mean age 57±11.38 
years.  The average HbA1c for all participants was 8.78%. Mean fasting plasma glucose 
concentration for the study population was 10.03mmol/l. The mean systolic and diastolic 
blood pressure of the study participants were within the target ranges of less than 
140/80mmHg.  The average BMI of both males and females were 31 and 32 respectively 
indicating that most participants were obese. Total cholesterol of the study participants 
(n=433) was 5.13mmol/L which is above the target of less than 4.5mmol/L. The participants 
were further analysed into respective target levels to establish the proportion of participants 
with results within and outside target as illustrated in Table 5.2.    
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Table 5.2 Demographic information of the study participants (n=575) stratified 
according to target and risk categories.  
Variable Stratification categories (range) 
HbA1c (%) Stable  At risk Decompensated   
              Low risk category  
              (29-35 years) < 6.5% 
2 11 0  
               Majority category  
               (35-55   years) <7% 
42 177 0  
               High risk category  
               (>55 years) <7.5% 
94 167 0  
Fasting plasma glucose (mmol/L) Stable 
<7  
At risk  Decompensated   
 130 444 0  
Systolic blood pressure (mmHg) Stable 
< 140mmHg 
Mild  
140-159 
Moderate  
160-179 
Severe  
180 or more 
 283 181 67 31 
Diastolic blood pressure (mmHg) Stable  
<80 
Mild  
80-99 
Moderate  
100-109 
Severe  
110 or more 
 238 292 27 5 
Body mass index (kg/m2) Normal  
<25 
Overweight  
25.0-29.9 
Mildly obese 
30.0-34.9  
Moderately 
obese 
                             Male  19 51 40 30 
                             Female          25 82 85 68 
 
Table 5.2 shows that a total of 138 participants had HbA1c results within target at baseline 
while a total of 355 participants had HbA1c results outside target. One hundred and thirty 
(23%) participants had FPG results within target and 444 (77%) outside target. These 
numbers shows that the majority of participants’ glycaemic levels either HbA1c or FPG were 
outside target ranges. A total of 98 participants had the decompensated systolic blood 
pressure and 32 had decompensated diastolic blood pressure. The table also shows that the 
total of 44 (11%) which is 19 males and 25 females had BMI levels less than 25kg/m2 which 
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is within target, while 356 (89%) participants, 121 male and 235 females had BMI levels 
above the recommended levels, indicating that majority of the study population was obese.   
5.2.1 Co-morbidities and complications 
The majority of T2DM patients in the study (93%) had been diagnosed with and were being 
treated for at least one other disease state. Only 7% (42) of the participants did not have other 
co-morbidities. Table 5.3 gives detailed information of participant’s co-morbidities and 
complications. 
Table 5.3 Co-morbidities and complications of participants (n=575) 
 Specific disease N=575 Prevalence (%) 
Cardiovascular diseases Hypertension, Ischaemic heart 
disease and coronary heart disease 
1 0.2 
Hypertension and coronary heart 
disease 
3 0.5 
Hypertension, ischaemic heart 
disease and dyslipidaemia  
3 0.5 
Hypertension and ischaemic heart 
disease 
6 1 
Hypertension, dyslipidaemia and 
cardiac congestive failure  
1 0.2 
Hypertension and cardiac congestive 
failure 
3  0.5 
Hypertension and dyslipidaemia 116 20 
Ophthalmic diseases Hypertension and glaucoma 1 0.2 
Hypertension and mild retinopathy 1 0.2 
Renal diseases Hypertension and chronic renal 
diseases 
1 0.2 
Peripheral vascular diseases  Hypertension and peripheral 
neuropathy 
2 0.4 
Complications  Blindness and hypertension 1 0.2 
None   42 7 
Dyslipidaemia only  17 3 
Hypertension only  377 66 
Total   575 100% 
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Table 5.3 shows that hypertension either alone (n=377) or in combination with other 
conditions was the most prevalent co-morbidity, followed by dyslipidaemia in combination 
with hypertension (n=116) and dyslipidaemia only (n=17).   
5.3 GLYCAEMIC MONITORING INDICATORS USED IN THE STUDY  
Glycaemic monitoring indicators that were used throughout the 18 months for which data 
was collected for the study participants included HbA1c and FPG. Figure 5.1 shows the 
number of HbA1c and FPG results of 575 participants taken during the 18 month period. 
HbA1c use declined throughout the eighteen month period from 86% of participants having 
one result, 2 results for 52% and only 10% of participants having three results. FPG use was 
almost constant throughout the 18 month period.   
 
 
Figure 5.1 The number of HbA1c and FPG results  recorded throughout the 18 months 
follow-up period (n=575) 
 
5.3.1 Assessment of glycated haemoglobin results of participants  
The last three HbA1c test results were recorded covering the 18 month period. Table 5.4 
summarises the average HbA1c readings of the three sets of results, stratified according to 
risk category.  
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Table 5.4 Summary of HbA1c results from initial reading (HbA1c 1) to most recent 
reading (HbA1c 3) according to risk category.  
 N=493 Mean ± 
standard 
deviation  
N=256 Mean ± 
standard 
deviation 
N=56 Mean ± 
standard 
deviation 
Low risk 13 8.154±1.62 7 8.043±1.33 1  
Majority  219 8.799±2.12 108 8.658±2.00 23 9.409±2.09 
High risk  261 8.749±2.37 141 8.853±2.39 
 
32 8.672±1.90 
Total  493  256  56  
 
Figure 5.2 shows the average HbA1c results as a percentage of participants who did not meet 
target at the different readings during the 18 month period. According to the figures >60% of 
participants had HbA1c consistently above recommended targets. 
 
  
Figure 5.2 Percentage of participants with glycated haemoglobin results outside target 
The initial HbA1c results were further used to determine if the difference between the actual 
results and the set target was significant i.e. not due to chance. Using a one-sample t-test (two 
tailed). Table 5.5 shows that HbA1c 1 results are significantly higher than target over all 
three risk categories.  
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Table 5.5 Initial HbA1c results for participants (n=493)  
Risk category  Number 
of 
results  
Within target 
(%) 
Outside target 
(%) 
Target 
value 
P-value 
Low risk  13 2 (15.4) 11 (85) 6.5 0.003 
Majority  219 42 (19) 177 (81) 7 0.000 
High risk 261 94 (36) 167 (64) 7.5 0.000 
Total  493 138 (28) 355 (72)   
   
Glycated haemoglobin results of participants who had more than one HbA1c result during the 
18 month follow-up period were further analysed to detect any sequential differences that 
could indicate an improvement or deterioration in diabetes management. For participants who 
had two HbA1c results (n=256) (HbA1c 1: 8.59±2.17; HbA1c 2: 8.75±2.23), no significant 
difference (p = 0.236) were observed between the initial and second results with a paired t-
test.  
5.3.2 Assessment of fasting plasma glucose results in participants   
Table 5.6 summarises the fasting plasma glucose results over the 18 month follow-up period. 
The total percentage of participants who had FPG result was 99% in first and subsequent test, 
with 94% of participants having a third result. Figure 5.3 distinguish FPG results into the 
percentages of participants who did not meet target at the different readings during the 18 
month follow-up period.  
Table 5.6 Summary of fasting plasma glucose results from the initial reading (FPG 1) to 
most recent reading (FPG 3).     
 Number of 
participants tested  
Mean ± standard 
deviation  
Minimum -maximum 
FPG 1 574 10.03±3.61 4.0-21.1 
FPG 2 574 10.24± 3.75 4.0-21.9 
FPG 3 541 10.09± 3.58 3.9-23.6 
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Figure 5.3 Percentage of participants with fasting plasma glucose results outside target  
 
Initial FPG results (FPG 1) indicate, 130 (23%) participants had the results within the target 
range while, 444 (77%) participants had the results outside the target range. The FPG results 
were further used to determine if the difference between the actual results and the set target 
was significant i.e. not due to chance. The target value for FPG is not individualized, that 
means there are no categories and <7mmol/L applies to all participants. The target value 
(7mmol/L) and the group mean (FPG 1 mean =10.03, standard deviation= 3.62) revealed a 
statistically significant difference (using one sample t-test, two-tailed) p=0.000. The second 
and the third FPG results when compared with the target value, also revealed the statically 
significant difference (using one paired t-test, two tailed) p=0.000.     
Fasting plasma glucose results of participants who had more than one FPG result during the 
18 month follow-up period were further analysed to detect any sequential differences that 
could indicate an improvement or deterioration in diabetes management. The means for FPG 
were compared at three different intervals to establish any differences; there was no statistical 
difference (using repeated measures ANOVA) in between the means as shown in Table 5.7. 
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Table 5.7 Association between FPG results for participants who had three consecutive 
tests (n=541) 
Time levels Mean  p-value 
FPG 1 (n=541) 10.01 ± 3.60 0.283 
FPG 2 (n=541) 10.25 ± 3.74 0.283 
FPG 3 (n=541) 10.09 ± 3.58 0.283 
 
5.3.3 Analysis of study participants’ gender, age and body mass index with 
respect to glycaemic results  
A multivariate analysis was done on the following variables; gender, age and body mass 
index to analyse for the correlation with glycaemic level. In participants with glycated 
haemoglobin, there was no correlation between age and HbA1c in low risk (p=0.275), 
majority (p=0.126) and the high risk (p=0.139) using Pearson correlation (for scale 
variables). This shows that attaining glycaemic control by HbA1c was not influenced by age 
or risk category. The relationship between gender and HbA1c was statistically significant 
with a  negative correlation (r=-0.647, p=0.031, two tailed) in participants in low risk with 
HbA1c outside target, this shows that the female in 29-34 years had the advantage of having 
good or low HbA1c results compared to their male counterparts using Spearman correlation 
(for nominal variables).   
There was no correlation between HbA1c and gender in participants with HbA1c results 
outside target in the majority category (34-55years) p= 0.387. In the high risk category 
gender did not have any correlation with HbA1c results outside target (p=0.860). Being male 
or female did not play any role in influencing HbA1c results in the majority and high risk, in 
participants with results within target in these age groups there was no correlation observed, 
with p=0.327 and 0.237 in majority and high risk respectively.   
The study population comprised of more obese participants, the BMI did not have any 
correlation with HbA1c results either within or outside target in all age groups. In the low 
risk category there was no correlation between BMI and HbA1c outside target (p=0.465), in 
the majority category with HbA1c outside target there no correlation with BMI being normal 
or obese (p=0.326 and p=0.695 respectively). In HbA1c within target in the same category, 
still there was no correlation with BMI and HbA1c (p=0.100).  
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In the high risk category, there was no correlation between BMI and HbA1c outside target 
among obese and healthy weight participants (p=0,979 and 0.547 in obese and healthy 
respectively). The same pattern was observed in participants with HbA1c results within 
target, there was no correlation observed in obese and healthy weight participants (p=0.866 in 
obese and 0.219 in healthy participants).  
In general the low risk female participants were shown to have a better chance of having 
good glycaemic control with HbA1c, than male of the same age or females in other age or 
risk categories. BMI did not have any significance across all age groups and gender in 
influencing the outcome of HbA1c.      
5.3.4 Analysis of the participants who had fasting plasma glucose results  
In participants with FPG results within target, there was no correlation between age and FPG 
in low risk (p=0.935, two tailed). In the majority category there was a correlation between 
age and FPG (r=0.181, p=0.005, two tailed) using Pearson correlation (scale variable) 
(n=238). In the high risk category there was no correlation between age and FPG results 
within target. This shows that only the majority category has the advantage of attaining better 
glycaemic control as compared to other age groups.   
Gender and FPG results within target has shown no correlation (p=0.298, two tailed) using 
Spearman correlation. This means that being a male or female does not have any impact on 
glycaemic control with respect to FPG. There was no correlation with BMI and gender 
(p=0.500, two tailed). Even though the results have shown that female were more likely to be 
obese. There was no correlation between BMI and gender in participants with FPG results 
within target.     
In participants with FPG results within target but obese, there was still no correlation between 
gender and BMI (p=0.784) and gender and FPG results (p=0.706, two tailed), using 
Spearman correlation. The results of participants within target have only shown a correlation 
between the 35-55 years age group and glycaemic control.  
In participants with FPG results outside target, there was no correlation between the low risk 
(29-34 years) and FPG (p=0.102). In the majority category there was a correlation between 
FPG and age (r=141, p=0.049, two tailed). This shows that the 34-55 age groups had an 
advantage of having good FPG results. In the high risk (>55 years) there was no correlation 
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(p=0.0201).  FPG results and gender had no correlation (p=0.176), gender did not have any 
impact on attaining or not attaining glycaemic control. Obesity or normal weight did not have 
any effect on FPG levels as results have shown a no correlation in both obese and healthy 
participants p= 0.148 and 0=371 in obese and healthy respectively.     
 
5.4 ASSESSMENT OF THE PHARMACOTHERAPEUTIC MANAGEMENT OF 
PARTICIPANTS 
A total of 3 prescriptions per participant were recorded, which amounted to 1 725 
prescriptions for 575 participants. The last 3 prescriptions written culminated in a minimum 
of 12 months and a maximum follow-up duration of 18 months (6 repeats / prescription).  
The anti-diabetics were grouped according to the following regimens: mono therapy, dual 
therapy, mono and insulin and dual and insulin. Mono therapy encompassed metformin or 
sulfonylurea monotherapy. Dual therapy were defined as a combination of metformin and a 
sulfonylurea. Then ‘mono and insulin’ included either metformin and insulin or a 
sulfonylurea and insulin. While ‘dual and insulin’ entailed; metformin, sulfonylurea and 
insulin.  
Anti-diabetic dosages and regimens of all participants were evaluated and analysed for any 
changes or adjustments made in follow-up prescriptions i.e. differences between prescription 
1 and prescription 2; and between prescription 2 and prescription 3. Adjustments were 
classified according to dosage changes and regimen changes.  Dose changes were classified 
as an increase or decrease in daily dose. Regimen changes were classified into step-up, step 
down or a lateral change. Step up regimen changes can be classified if the change was 
upwards i.e. from mono to dual therapy, from dual to triple therapy, and, from dual to mono 
and insulin. Step down regimen changes would be defined as the opposite of step up. Lateral 
changes were a switch in drug within the same regimen for example if sulphonylureas was 
changed to metformin or vice versa. Table 5.8 provides a summary of treatment regimens and 
regimens changes recorded in all participants over the course of the three prescriptions.    
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Table 5.8 Summary of treatment regimens and adjustments for 3 consecutive prescriptions in the 575 participants  
 
 
Treatment 
regimen
Anti-diabetic 
agent 
Prescription 
1
Prescription
2
no change 
between 
P1 & P2
Daily dose 
increased
Daily dose 
decreased
Step-up 
regimen
Step down 
regimen
Lateral 
regimen 
change Prescription2 Prescription3
no change 
between 
P2 & P3
Daily dose 
increased
Daily dose 
decreased
Step-up 
regimen
Step down 
regimen
Lateral 
regimen 
change
Mono therapy Metformin 198 189 175 6 1 14 0 2 189 196 174 8 0 5 0 2
Gliclazide 23 20 17 1 0 3 0 2 20 13 11 0 0 1 0 8
Glimepiride 0 7 0 0 0 0 0 0 7 15 7 0 0 0 0 0
Glibenclamide 5 0 0 0 0 1 0 4 0 0 0 0 0 0 0 0
Dual therapy
Metformin + 
Gliclazide 181 188 149 13 7 4 3 5 188 106 94 5 2 1 11 75
Metformin + 
glimepiride 11 30 8 0 0 0 2 1 30 115 26 1 0 0 1 2
Metformin + 
glibenclamide 44 29 22 1 0 0 1 20 29 14 13 0 0 0 3 13
Mono + insulin
Metformin + 
insulin 51 50 32 7 2 0 0 10 50 56 39 2 1 0 2 6
Gliclazide + 
insulin 7 7 4 2 0 0 0 1 7 6 6 0 0 0 0 1
Glimepiride + 
insulin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Glibenclamide + 
insulin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Dual + insulin
Metformin + 
Gliclazide + 
Insulin 43 42 22 6 3 0 3 9 42 26 13 6 1 0 4 18
 Metformin + 
Glimepiride + 
insulin 4 8 3 1 0 0 0 0 8 26 7 0 0 0 0 1
Metformin + 
glibenclamide + 
insulin 8 5 4 1 0 0 1 2 5 2 2 0 0 0 0 3
Total 575 575 436 38 13 22 10 56 575 575 392 22 4 7 21 129
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Table 5.9 summarises the overall treatment regimens and adjustments for all participants 
(n=575) from prescription 1 to prescription 2 and prescription 2 to prescription 3.  The results 
revealed that between prescription 1 and prescription 2, out of 575 participants, 75.8% did 
not have any therapy adjustments, 6.6% had the total daily dose increased, 2.3% had the total 
daily dose decreased, 3.8% had a step–up in regimen and 1.7% had a step-down and 9.7% 
had a lateral change in regimen. The changes between prescription 2 and prescription 3 
revealed that, 68.1% did not have any therapy adjustments, 3.8% had the total daily dose 
increased, 0.7% had the total daily dose decreased, 1.2% a step-up in regimen and 3.7% had a 
step down and 22.4% had lateral changes made to their regimen. 
5.4.1 Analysis of treatment regimens  and therapy adjustments in 
participants who had glycated haemoglobin results  
For this section, only participants who had HbA1c results available at the time of the issuing 
of the prescription were included in the analysis. A total of 133 participants had HbA1c 
results recorded that fell between the dates between prescription 1 and prescription 2. The 
treatment regimen adjustments of these 133 participants were separated according to those 
with results that fell within target (n=38) and outside target range (n=95). It was found that in 
38 participants who had initial HbA1c results within target, 78.9% participants did not have 
any therapy adjustment, 7.9% had the total daily dose increased, no one had the daily dose 
decreased and no one had a step-up regimen, while 10.5% had the step down regimen and 
2.6% had a lateral change in regimen (Appendix 7).     
Appendix 8 summarises the treatment regimen and adjustments from prescription 1 to 
prescription 2 of participants with HbA1c results outside target (n=95). The results revealed 
that out of 95 participants, 60% did not have any therapy adjustments, 17.9% had the total 
daily dose increased, 3.1% had total daily dose decreased, 8.4% had a step-up in regimen, 
3.1% had a step down in regimen and 7.4% had the lateral regimen.   
 
 
 
 
61 
 
A total of 112 participants had HbA1c results recorded that fell between the dates of 
prescription 2 and prescription 3. The treatment regimen adjustments of the 112 participants 
were separated according to those results that fell within target (n=26) and outside target 
range (n=86). It was found that in 26 participants who had HbA1c results within target, 73% 
participants did not have any therapy adjustments, and no one had dose changes or a step-up 
in regimen, while 3.8% had a step-down in regimen and 23.1% had a lateral change in 
regimen (Appendix 9). 
Appendix 10 summarises the treatment regimens and adjustments from prescription 2 to 
prescription 3 of participants with HbA1c 2 results outside target range (n=86). The results 
revealed that out of 86 participants, 65.1% did not have any therapy adjustments, 2.3% had 
the total daily dose increased, 3.4% had the total daily dose decreased, 1.2% had a step-up in 
regimen, 2.3% had a step down in regimen, and 25.6% had a lateral change in regimen.           
Figure 5.4 shows the summary of therapy adjustments for the participants with HbA1c results 
within target and outside target ranges for the 18 month follow-up period. Most participants 
had no change in their prescriptions, 76.6% of participants within target did not have any 
therapy adjustments and 62.4% of participants outside target did not have any therapy 
adjustments.  
 
Figure 5.4 Summary of therapy adjustments in participants with glycated haemoglobin 
results within and outside target 
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5.4.2 Analysis and determination of treatment regimens in participants who 
had fasting plasma glucose results 
For this section, only participants who had FPG results available at the time of the issuing of 
the next prescription were included in the analysis. A total of 553 participants had FPG 
results recorded at a date between prescription 1 and 2. The treatment regimens of 
participants with FPG results within target (n=120) and results outside target (n=433) ranges 
were analysed separately to determine rational therapy adjustments. Appendix 11 shows that 
of the 120 participants who had FPG results within target available at the time of writing 
prescription 2, 82.5% did not have any therapy adjustments, 3.3% had the total daily dose 
increased, 1.7% had the total daily dose decreased, 4.2% had a step-up in regimen, 0.8% had 
a step down in regimen and 7.5% had a lateral regimen change. 
Appendix 12 summarises the treatment regimens and adjustment from prescription 1 to 
prescription 2 of the participants with FPG results outside target (n=433). The results 
revealed that out of 433 participants, 76% did not have any therapy adjustments, 6.7% had 
the total daily dose increased, 3.2% had the total daily dose decreased, 2.5% had a step-up in 
regimen, 2.3% had a step down in regimen and 9.2% had a lateral regimen change.   
A total of 537 participants had FPG results recorded that fell between the dates between 
prescription 2 and prescription 3. The treatment regimen adjustments of the 537 participants 
for those that results fell within and outside target ranges were analysed separately to 
determine rational therapy adjustments. It was found that in 118 participants who had FPG 
results within target, 77.1% participants did not have any therapy adjustments, 3.4% had total 
daily dose increased, no one had a daily dose decrease or step-up in regimen, 5.9% had a 
step-down in regimen and 13.6% had a lateral regimen change (Appendix 13). 
Appendix 14 summarises the treatment regimens and adjustments from prescription 2 to 
prescription 3 of participants with FPG results outside the target range (n=419). The results 
revealed that out of 419 participants, 66.8% did not have any therapy adjustments, 4.3% had 
the total daily dose increased, 1% had the total daily dose decreased, 1.2% had a step-up in 
regimen, 1.2% had a step down in regimen and 25.5% had a lateral regimen change. 
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Figure 5.5 shows the summary of therapy adjustments for the participants with FPG results 
within target and outside target for the 18 months follow-up period. Most participants had no 
in their prescriptions, 79.8 % of participants within target had no therapy adjustments and 
71.5% of participants outside target had no therapy adjustments.   
 
 
Figure 5.5 Summary of therapy adjustments in participants with fasting plasma glucose 
results within and outside target 
 
5.5 SUMMARY OF THE CHAPTER 
In this chapter demographics of the study population, glycaemic monitoring indicators used 
in the study and assessment of the pharmacotherapeutic management of participants were 
presented. 
Discussion of the results follows in the next chapter.
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CHAPTER 6: DISCUSSION 
6.1 INTRODUCTION  
The findings of the study will be discussed in this chapter. Assessment of management  of 
type 2 diabetes mellitus using glycated haemoglobin and fasting plasma glucose as 
monitoring parameters will be discussed first followed by prescribing patterns in patients 
whose monitoring parameters are not at target using evidence-based guidelines. Lastly 
therapy adjustments will be discussed. 
6.2 DESCRIBING GLYCATED HAEMOGLOBIN AND FASTING PLASMA 
GLUCOSE ACCORDING TO RISK STRATIFICATION AS PER EVIDENCE-
BASED MANAGEMENT GUIDELINES   
6.2.1  Demographics of the study population 
The study consisted of 575 patient treated at 5 community health centres in the Cape Town 
Metropolitan region South Africa with a mean age 57±11.38. Patients were categorized 
according to various age groups. The 29 to 34 years age category consisted of 14 participants, 
the 35 to 55 years age category  consisted of 238 while participants of >55 years of age  
consisted of 323 participants highlighting the fact that T2DM is more prevalent in the older 
population.  The age distribution of this study corresponds with the global trends of T2DM 
where by it was found that diabetes prevalence seems to be increasing more in older people  
(Wild et al. 2004).  Similar results were reported in a South African study in Cape Town 
(n=200), whereby 28.7% of participants from mixed origin aged 65 years and older were 
found to have T2DM (Erasmus et al. 2012). The majority of study participants were female 
with 64% and male 36%. The predominance of the female participants in the study 
population is similar with previous South African studies, whereby Motala et al (2003) 
reported a study population of 60% females and 40% males that assessed the prevalence and 
knowledge of DM in the public clinics and the community (Moodley & Rambiritch 2007).  
The mean HbA1c for the study was 8.78%. While the fasting plasma glucose mean was 
10mmol/L which is also above the recommended target of less than 7mmol/L. The findings 
from this study concur with the findings of the study performed in the public sector in three 
major academic hospitals served by the University of the Witwatersrand namely: 
Johannesburg, Helen Joseph and Baragwanath, where the mean HbA1c for the study 
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participants (n=150) was 8.7% (Klisiewicz & Raal 2009). Amod et al (2012) in a study done 
in the private sector of South Africa has also reported the mean HbA1c of 8.2%. The mean 
FPG of greater than 7mmol/L was found in a study done in the rural black community in 
Limpopo with the prevalence rate of 8% and 9% in male and female respectively (Alberts et 
al. 2006). This indicates that despite the available evidence from clinical trials, that supports 
the need for achieving recommended targets, the management of diabetes patients in South 
Africa is still largely sub optimal (Klisiewicz & Raal 2009). 
The mean systolic blood pressure of the participants was 139.6mmHg and mean diastolic 
blood pressure was 79.9mmHg which concurs with the latest targets of less than 
140/80mmHg in T2DM patients set out by the guidelines (Society for endocrinology 
metabolism and diabetes South Africa (SEMDSA) 2012). This findings of blood pressure 
concurs with the findings of the study performed in the private sector in Durban, it was found 
that in contrast to other studies done elsewhere in the world, the South African patients’ 
blood pressure is relatively well controlled whereby participants (n=899) had mean systolic 
blood pressure of 131.4mmHg and mean diastolic pressure of 79.4mmHg (Amod et al. 2012)   
The mean BMI of 32 and 30.72 in females and males was reported which was higher than the 
BMI that was reported in a study done in Bellville Cape Town, where by the study found the 
BMI of 30.8 in females and 25.8 in males (Erasmus et al. 2012 ).  Change in diet to more 
saturated fats and sugars is largely responsible for high rates of obesity characterising the 
emergence of non-communicable diseases in South Africa, this was observed in a study 
conducted among urban dwelling black South Africans which showed a strong association 
between increased body weight and diabetes mellitus (Peer et al. 2012). Wang et al (2005) 
had found that high BMI alone strongly and independently predict risk of T2DM.  
Total cholesterol levels of the study participants were higher (5.13mmol/L) than the 
recommended target levels (< 4.5mmol/L), which explains why there was an observed high 
prevalence of study participants with dyslipidaemia. Three hundred (69%) participants had 
total cholesterol above 4.5mmol/L, which is also alarming and positive determiner in 
cardiovascular diseases. Norman et al (2007) had indicated that 59% of ischaemic heart 
disease and 29% of ischaemic stroke in South Africa are attributable to raised cholesterol 
levels, which compares with the world wide estimates of 32%.  
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Studies have revealed that the prevalence and incidence of cardiovascular diseases is 
increased in patients with T2DM, this concurs with the findings of this study which have 
revealed that 93% of the study participants with co-morbidities had cardiovascular diseases. 
Of these diseases the most prevalent were hypertension either diagnosed alone or with other 
diseases 516 (80%) and dyslipidaemia either alone or with other diseases 133 (20%). Girach 
& Vignati (2006), in a systematic review study have found that the presence of one 
microvascular complication predicts the development of another. The results of the study 
concurs with the results of the study that was done in the peri-urban black South Africans in 
Cape Town where by an optimal control of 33% and 44% was found in men and women 
respectively (Dennison et al. 2007). 
6.2.2 Glycated haemoglobin  
As described earlier in the discussion and in the literature the glycaemic results were analysed 
with a specific target value for every risk category. Four hundred and ninety three 
participants (86%) had at least one HbA1c result. The average mean HbA1c results in all risk 
categories throughout the 18-months follow-up period were above the targeted percentages of 
6.5% for the low risk, 7% for the majority and 7.5% for the high risk. The percentage of 
participants who did not meet target at the different readings was higher than the percentages 
of participants who were within target. The initial HbA1c results have shown that only 138 
(28%) of participants were within target, hence the poor glycaemic control of the 335 (72%) 
participants is of concern. The findings of this study concurs with the findings of the study 
done in the public sector in three academic teaching hospitals in Johannesburg that had found 
the mean HbA1c of 8.7% for all study participants (Klisiewicz & Raal 2009).  Motala et al 
(2012) in a study done in a private sector had reported similar results of 8.7% which also 
concurs with the results of this study of mean HbA1c of 8.78%.   
6.2.3 Fasting plasma glucose results of participants 
Fasting plasma glucose was the predominantly used glycaemic monitoring test almost 
everyone had the test done throughout the study period. In the three consecutive test results 
the mean FPG was above 7mmol/L. From the initial FPG results 130 (23%) participants had 
the results within target range, while 444 (77%) participants had the results outside target. 
The percentage of participants outside target was maintained at above 77%, indicating that 
the glycaemic levels of participants were never satisfactorily controlled. Nthangeni et al. 
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(2002) had found poor glycaemic control in more than half of the study participants having 
FPG above 8mmol/L, which is the case in the present study done more than ten years later 
indicating an urgent need in glycaemic control.      
6.2.4 Analysis of study participants’ gender, age and body mass index with 
respect to glycaemic results 
A significant negative association was found between a female gender and HbA1c outside 
target in low risk participants. Meaning that the younger the patient the higher the chances of 
having improved HbA1c levels. A significant positive association was found between 
majority age group and FPG. Participants in this age group had the advantage of having better 
FPG control than the other participants. 
Surprisingly enough there was no correlation between gender, BMI, FPG and HbA1c. None 
of these were found to influence either HbA1c or FPG control of the study participants. 
Given the high prevalence of obesity and the number of high number of female participants 
in high risk group, it would have been expected that there a significant association with 
HbA1c and FPG results outside target.  
6.3 PRESCRIBING PATTERNS IN PATIENTS WHOSE MONITORING 
PARAMETERS ARE NOT AT TARGET USING  EVIDENCE-BASED 
MANAGEMENT GUIDELINES  
Glycaemic control is achieved by pharmacotherapy that targets fasting and postprandial 
glucose levels, as well as HbA1c (Sherifali et al.2010). The therapeutic management involves 
the use of oral hypoglycaemic agents and insulin, either as monotherapy, or in combination 
(Nathan et al. 2009). The four treatment regimens namely; mono therapy, dual therapy, mono 
and insulin and dual and insulin, in the management of T2DM patients were prescribed. The 
Department of Health (2008) guidelines encourage the use of a stepwise treatment approach 
to adjusting therapy in the management of T2DM to reach glycaemic targets, while SEMDSA 
(2012) has further endorsed this by establishing individualized targets to reach glycaemic 
target levels. Most participants were on dual therapy (41%), followed by mono therapy 
(39.3%) and few were on mono and dual with insulin (10.1 % and 9.6% respectively). The 
study results concurs with the findings of the study done in the private sector in Durban, it 
was found that using triple therapy is not a common practise in South Africa insulin initiation 
is only done after a failure of dual therapy (Amod et al 2012). Therapy adjustments, daily 
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dose increases and step-up in regimen would be expected in participants with glycaemic 
results outside target range. Daily dose decreases, step down in regimen or lateral change in 
regimen would be expected in participants within target range, or due to side effects and 
changes in essential medicines list.  
6.3.1 Therapy adjustments in participants monitored by glycated 
haemoglobin  
The total amount of opportunities to happen for intervention in participants with HbA1c 
results outside target were 181, 113 (62.4%) did not have any therapy adjustments, 19 
(10.5%) had the total daily dose increased, 6 (3.3%) had total daily dose decreased, 9 (5.0%) 
had a step-up in regimen, 5 (2.8%) had a step down in regimen and 29 (16.0%) had a lateral 
regimen in prescription 1 and prescription 2. Taking into consideration that the study cohort 
is composed of participants with cardiovascular diseases, obese and high HbA1c levels above 
recommended targets more therapy adjustments specifically dose increases and step up in 
regimen would be expected in participants with results outside target. There were 64 
opportunities for intervention to happen in participants with HbA1c results within target, 49 
(76.6%) did not have therapy adjustments, 3 (4.7%) had the total daily dose increased, no one 
had the daily dose decreased and had a step-up in regimen, 5 (7.8%) had a step down in 
regimen and 7 (10.9%) had a lateral change in regimen. From the participants with results 
within target, dose decrease, step-down in regimen and lateral regimen would be expected 
because of side effects or changes in essential medicines list. Intensive glycaemic control was 
shown to reduce microvascular complications in Japanese T2DM patients in the Kumamoto 
study, this shows that therapy adjustments can improve glycaemic control and delay the 
progression of the disease (Ohkubo et al. 1995). Diabetes treatment is adjusted based on 
HbA1c results (Nathan et al. 2008). Large controlled clinical trials have found that in patients 
with T2DM improved glycaemic control is associated with reductions in macrovascular 
complications (UK Prospective Diabetes Study (UKPDS) Group 1998; Stettler et al. 2006). 
6.3.2 Therapy adjustments in participants monitored with fasting plasma 
glucose  
The total amount of opportunities to happen for intervention in participants with FPG results 
outside target were 852, 609 (71.5%) did not have any therapy adjustments, 47 (5.5%) had 
the total daily dose increased, 18 (2.1%) had the total daily dose decreased, 16 (1.9%) had a 
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step-up in regimen, 15 (1.8%) had a step down in regimen and 147 (17.3%) had a lateral 
change in regimen in prescription 1 and 2. Fasting plasma glucose shows glucose levels for 
only eight hours (DoH 2008). Understanding the relationship between HbA1c and average 
glucose by prescribers can be useful in adjusting therapy (SEMDSA 2012). There were 238 
opportunities for intervention to happen in participants with FPG results within target, 190 
(79.8%) did not have any therapy adjustments, 8 (3.4%) had the total daily dose increased, 2 
(0.8%) had the total daily dose decreased, 5 (2.1%) had a step-up in regimen, 8 (3.4%) had a 
step down in regimen and 25 (10.5%) had a lateral change in regimen.   
6.3.3 Rational use of medicines 
The prescribing patterns and therapy adjustments of participants with glycaemic results 
outside target and glycaemic results within target ranges are similar. The regimens were not 
adjusted as per the results and the change of drug within the same regimen with the same 
mean lowering of HbA1c is not sufficient to respond to the glycaemic levels. Inappropriate 
doses do not respond effectively in the management of the disease, hence resulting in serious 
morbidity and mortality (WHO 2002). The guidelines have endorsed a benchmark for which 
comparison can be made to promote rational use of medicines in the management of diseases 
if used appropriately (WHO 2002).   
6.4 STUDY LIMITATIONS 
Limitations relating to information not available in patient medical record: 
• Date of first diagnosis was not available in the patient medical records, therefore 
duration of the participant with T2DM could not be established, so co-morbidities or 
complications could not be linked to the duration which is important.   
• Information on lifestyle interventions e.g. smoking alcohol use, diet and physical 
activity was not routinely collected.   
• Information on complete lipid profile was not available, only total cholesterol was 
there, making it difficult to comment on the management of dyslipidaemia.  
• Information on ethnicity was not included, (it was derived from the name hence not 
reliable) therefore could not be analysed, which is important in analysing the 
prevalence of T2DM per ethnic group.  
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The study was conducted in 5 primary health centres in the public sector, which is used by 
public patients only, furthermore the general population of the database was used as the study 
population, thus the results of this study may not be representative of the trends and patterns 
in the population of South Africa as it reflects patterns in public practise only without 
considering private sector. Caution needs to be exercised when generalising the results.       
6.5 SUMMARY OF THE CHAPTER  
The management of T2DM using HbA1c and fasting plasma glucose as monitoring tools 
were discussed.  The discussion further focused on medicine adjustments in patients outside 
glycemic target ranges, with an emphasis on the various categories for risk stratification. 
Appropriate use of evidence-based guidelines contributes to rational use of anti-diabetic 
medicines in patients with T2DM.  The chapter is concluded describing the limitation of the 
study.   
Conclusions to the above findings are discussed in the following chapter. 
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CHAPTER 7: CONCLUSION AND RECOMMENDATIONS  
7.1 INTRODUCTION  
The study aimed to describe the use of glycaemic monitoring indicators in patients with 
T2DM, classified as stable, treated at primary health care facilities in the Cape Town 
Metropolitan Region in South Africa. The study will hopefully contribute to reducing the 
burden of the disease through early interventions and identification of cases that needs special 
attention, by being able to identify the at-risk population, improving long term management 
and minimising the development of complications associated with diabetes.  It is assumed 
that there will be a contribution to reduction on health care expenditure with appropriate and 
rational use of medicines. 
7.2 SUMMARY OF FINDINGS 
This study has demonstrated  that from the medical records of 575 patients with T2DM 
managed at 5 different primary healthcare facilities; FPG was the most often used glycaemic 
monitoring indicator, glycaemic monitoring of patients  mostly show suboptimal glucose 
control and that opportunities to optimise pharmacotherapy in diabetes management are 
mostly missed. In terms of the gold standard of glycaemic monitoring indicators, HbA1c was 
used less (86% of participants had at least one result) and in decreasing frequency (52% had 
two results and only 10% had three results) as compared to FPG. 
Most patients showed suboptimal glucose control, despite the fact that the target population 
of the study were patients classified as stable by the primary health care clinic. In addition, 
longitudinal glycaemic monitoring results of both FPG and HbA1c showed no improvement 
over the 18 month follow-up period. This corresponds to the third main finding that showed 
no correlation between pharmacotherapy adjustments and the glycaemic monitoring results.   
This indicates that HbA1c results were not used to direct treatment changes where necessary, 
resulting in sub-optimal management of type 2 diabetes mellitus. Similar prescribing patterns 
were observed in patients with glycaemic results within target ranges as well as glycaemic 
results outside target ranges. It would be expected that there will not be therapy adjustments 
made in participants with glycaemic results within target ranges except in patients with 
adverse effects of drugs or change in essential medicines list which were not documented in 
patient medical folders, however, management of this population group were  similar to 
patients with glycaemic results outside target.    
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In conclusion, chapter 2 and 3 described the health care system in South Africa and the 
importance of appropriate management of T2DM.  The national department of health has 
made non-communicable disease a health priority as the burden on the health care system as 
well as burden on the patient’s well-being. Evidence-based management guidelines are 
available for the appropriate and effective management of T2DM.  This study is contributing 
to the available evidence in the literature regarding the current management challenges of 
T2DM, especially in the public health care sector of SA. Even though guidelines for effective 
treatment are available, a large number of patients accessing health care services for T2DM 
are not receiving adequate treatment, which potentially strains the health care system as well 
as decreases the quality of the life of those patients. 
7.3 RECOMMENDATIONS  
Health care workers should be educated on the appropriate use and interpretation of HbA1c at 
clinic level. Laboratory investigations recommended by guidelines for effective management 
of diabetic patients, specifically TDM2, should be done accordingly. Adherence to treatment 
guidelines should be promoted to improve rational use of medicines. Guideline 
implementation should be a priority for policy-makers and facility managers.  There are 
currently poor implementation practices seen at health facilities.    
 
A standardised patient medical folder should be used in every facility where stable TDM2 
patients are treated.   From the recent study conducted in health care facilities it was observed 
that there were inconsistencies with regards to documentation of TDM2 patient care.  It is 
recommended that complete documentation be done in terms of social history, past 
medication history, laboratory investigations and patient education. This will allow for 
seamless patient care.   
Future research should investigate the determinants of poor glycaemic control both for the 
prescriber and patient. Future research should also investigate whether prescribers are aware 
of the target ranges for various monitoring parameters used in TDM2.   This again highlights 
the importance of guideline implementation. 
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APPENDIX 1: DATA COLLECTION SHEET 
          
              Unigue ID of the patient 
           Date of collection 
            Captured by: 
            
     
Sex : 
M/F 
 
Stratification category: 
 
Stable 
  Date of birth 
   
Smoking: Y/N 
    
At risk 
  Race/ethinicity: Black African, 2. Coloured Alcohol use: Y/N 
    
Decompensated 
 
  
3. 
Indian  
4. 
White 
 
Allergies: Y/N Date stratified: 
     
              Medical history            
                     
         
     
  
                     
                     
       
              Monitoring Tests 
            TESTS not done date results date results date  results date results date results date results 
HbA1c                           
FPG                           
PPG                           
BP                           
K                           
Na                           
Urea                           
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Waist Cir                           
Foot exam                         
Fundoscopy                         
Creatinine                           
Proteinurea                         
GFR                           
BMI                           
Height                           
Weight                           
Lipids profile                         
LDL                           
HDL                           
Triglycerides                         
Cholesterol                         
Urine Dipstik                         
Glucose                           
Protein                           
Ketones                           
Nitrite                           
Haemoglobin                         
Bilirubin                           
Urobilinogen                         
Acetone                           
Leucocytes                         
PH                           
Specific gravity                         
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Date of first prescription 
  
Date Date Date Date 
     drugs     dose frequency Repeat  Repeat Repeat Repeat 
       
 
              
                       
       
 
              
                       
                       
       
 
              
                       
                       
                       
                       
     
              Date of first prescription 
  
Date Date Date Date 
     drugs     dose frequency Repeat Repeat Repeat Repeat   
   
  
  
 
          
 
  
                       
       
 
              
                       
                       
       
 
              
                       
                       
                       
     
              Date of first 
prescription 
    
Date Date Date Date 
     drugs     dose frequency Repeat Repeat Repeat Repeat 
       
 
              
                       
       
 
              
                       
                       
       
 
              
                       
                       
                       
                       
      
 
 
 
 
88 
 
APPENDIX II: UWC ETHICS APPROVAL 
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APPENDIX III: WESTERN CAPE APPROVAL 
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APPENDIX IV: UNIQUE IDENTIFIER 
Unique ID Name  surname Date of birth ID number Clinic name Number Folder  Date captured 
001        
002        
003        
004        
005        
006        
007        
008        
009        
010        
011        
012        
013        
014        
015        
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APPENDIX V: INFORMATION SHEET 
Project Title: Rational drug therapy monitoring in type 2 diabetes mellitus: using glycated 
haemoglobin as a guide for change in therapy 
What is this study about?  
This is a research project being conducted by Khathatso Monanabela a student at the University of the 
Western Cape. The purpose of this study is to describe the use of glycaemic monitoring indicators in 
patients with type 2 diabetes mellitus, classified as stable, treated at primary health care facilities in 
the Cape Town Metropolitan Region in South Africa. Your facility has been purposefully selected for 
our data collection.  
What will I be doing at the facility? 
I will be capturing data into my data collection sheet from your patient medical records. We will be 
identifying patients from your facility through the electronic chronic dispensing unit’s (CDU) 
database. This database provides all the names of stable chronic patients managed at your facility. 
Patients with Type 2 Diabetes Mellitus should appear on this database and will be identified as those 
treated with oral anti-diabetics and insulin. The final selection of patients will only occur once their 
medical records concur with the following inclusion and exclusion criteria. The inclusion criteria in 
the study include patients older than 18 years of age, who have been diagnosed with Type 2 Diabetes 
Mellitus, on treatment for a minimum of 6 months and who have been categorised as stable. 
Exclusion criteria include all patients younger than 18 years of age, patients with Type 1 diabetes 
mellitus, those who have been on treatment for less than 6 months and categorised as ‘at risk’ or 
decompensated. 
How will I keep the identity of your patients confidential? 
The anonymity of your patients will be ensured by the assignment of a unique identifier for each 
patient enrolled in the study. Before data collection from the patient medical record ensues, a unique 
identifier will be assigned to each new participant via a master copy form. The data collection tool 
will only contain the unique identifier assigned to the patient.  The master copy form with the 
identifying information will be kept separate from the data collection sheets and will be available only 
for senior researchers involved in the study to verify and link patient identities across the databases. In 
the two electronic databases using in the study, that is, CDU will be password protected. This 
information, together with the data collection tool, will be kept at the School of Pharmacy of the 
University of the Western Cape. Once the study is completed i.e. research reports and publications 
written, the electronic databases and paper data collection tools will be deleted and destroyed by the 
principle researcher. 
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What are the risks of this research? 
The risks for study participants are minimal as the anonymity protection will ensure confidentiality. 
What are the benefits of this research? 
No direct benefits for the study participants are anticipated. However, indirect benefits might include 
a better understanding of the use of glycated haemoglobin in the management of Type 2 Diabetes 
Mellitus at primary health care facilities which might be followed by recommendations and training to 
improve Type 2 Diabetes Mellitus management overall. 
How did I get permission to access to your facility?   
The researcher had to submit and obtain approval from two committees namely, the University of the 
Western Cape Ethics Committee and the Western Cape Provincial Health Research Committee before 
the study was to be conducted.  
What if you have questions? 
This research is being conducted by Khathatso Monanabela, a student pursuing a Masters in 
Pharmacy at the University of the Western Cape.  If you have any questions about the research study 
itself, please contact; Khathatso Monanabela, Tel 0794456664, kmonanabela@gmail.com. 
Should you have any questions regarding this study or if you wish to report any problems you have 
experienced related to the study, please contact:   
Research supervisor: Dr Renier Coetzee 
School of Pharmacy 
University of the Western Cape 
Tel; 0219593665 
Private Bag X17 
Bellville 7535  
South Africa              
This research has been approved by the University of the Western Cape’s Senate Research Committee 
as well as the Western Cape Provincial Health Research Committee 
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APPENDIX VI: CONSENT FORM 
Title of Research Project:  Rational drug therapy monitoring in type 2 diabetes mellitus: using 
glycated haemoglobin as a guide for change in therapy 
The study has been described to me and my questions about the study have been answered. I 
understand that the researcher had obtained permission to conduct the study from University of the 
Western Cape’s Senate Research Committee as well as the Western Cape Provincial Health Research 
Committee. I understand that the researcher will need access to patient medical records at this 
facility. 
Participant’s name………………………..   
Participant’s signature………………                                 
Date……………………… 
Should you have any questions regarding this study or wish to report any problems 
you have experienced related to the study, please contact the study supervisor: 
Research supervisor: Dr Renier Coetzee 
School of Pharmacy 
University of the Western Cape 
Tel; 0219593665 
Email: recoetzee@uwc.ac.za  
Private Bag X17 
Bellville 7535  
South Africa     
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APPENDIX VII: Treatment regimens and changes in glycated haemoglobin results within target at the 
time of writing prescription 2 (n=38) 
Treatment 
regimen 
Anti-diabetic 
agent  
Prescription 
1 
Prescription2 no 
change 
between 
P1 & P2 
Daily 
Dose 
increased 
Daily 
Dose 
decreased 
Step-up 
regimen 
Step 
down 
regimen 
Lateral 
regimen 
change 
Mono 
therapy 
Metformin 21 21 18 2 0 0 0 1 
 Gliclazide  0 1 0 0 0 0 0 0 
 Glimepiride 0 0 0 0 0 0 0 0 
 Glibenclamide 0 0 0 0 0 0 0 0 
Dual therapy Metformin + 
Gliclazide 
10 10 9 0 0 0 1 0 
 Metformin + 
glimepiride 
0 2 0 0 0 0 0 0 
 Metformin + 
glibenclamide 
4 1 1 0 0 0 3 0 
Mono + 
insulin 
Metformin + 
insulin 
2 2 1 1 0 0 0 0 
 Gliclazide + 
insulin  
0 0 0 0 0 0 0 0 
 Glimepiride + 
insulin 
0 0 0 0 0 0 0 0 
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 Glibenclamide 
+ insulin 
0 0 0 0 0 0 0 0 
Dual + 
insulin 
Metformin + 
Gliclazide + 
insulin 
1 1 1 0 0 0 0 0 
 Metformin + 
glimepiride + 
insulin 
0 0 0 0 0 0 0 0 
 Metformin + 
glibenclamide 
+ insulin 
0 0 0 0 0 0 0 0 
Total   38 38 30 3 0 0 4 1 
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APPENDIX VIII: Treatment regimens and  changes in glycated haemoglobin results outside target at the 
time of writing prescription 2 (n=95) 
Treatment 
regimen 
Anti-diabetic 
agent  
Prescription 
1 
Prescription2 no 
change 
between 
P1 & P2 
Dose 
increase
d 
Dose 
decreased 
Step-up 
regimen 
Step 
down 
regimen 
Lateral 
regimen 
change  
Mono therapy Metformin 30 23 20 2 1 7 0 0 
 Gliclazide  4 2 2 0 0 1 0 1 
 Glimepiride 0 2 0 0 0 0 0 0 
 Glibenclamide 1 0 0 0 0 0 0 1 
Dual therapy Metformin + 
Gliclazide 
27 34 22 3 1 0 0 1 
 Metformin + 
glimepiride 
2 3 1 0 0 0 0 1 
 Metformin + 
glibenclamide 
3 4 2 0 0 0 0 1 
Mono + 
insulin 
Metformin + 
insulin 
11 12 5 6 0 0 0 0 
 Gliclazide + 
insulin  
2 2 1 1 0 0 0 0 
 Glimepiride + 
insulin 
0 0 0 0 0 0 0 0 
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 Glibenclamide 
+ insulin 
0 0 0 0 0 0 0 0 
Dual + insulin Metformin + 
Gliclazide + 
insulin 
9 7 3 2 1 0 3 0 
 Metformin + 
glimepiride + 
insulin 
2 4 1 1 0 0 0 0 
 Metformin + 
glibenclamide 
+ insulin 
4 2 0 2 0 0 0 2 
Total   95 95 57 17 3 8 3 7 
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APPENDIX IX: Treatment regimens and  changes in glycated haemoglobin results within target at the 
time of writing prescription 3 (n=26) 
Treatment 
regimen 
Anti-diabetic 
agent  
Prescription2 Prescription3 no 
change 
between 
P2&P3 
Daily 
dose 
increased 
Daily 
dose 
decreased 
Step-up 
regimen 
Step-
down 
regimen 
Lateral 
regimen 
change 
mono therapy Metformin 13 14 13 0 0 0 0 0 
 Gliclazide  0 0 0 0 0 0 0 0 
 Glimepiride 1 1 1 0 0 0 0 0 
 Glibenclamide 0 0 0 0 0 0 0 0 
Dual therapy Metformin + 
Gliclazide 
5 1 1 0 0 0 1 3 
 Metformin + 
glimepiride 
1 7 1 0 0 0 0 0 
 Metformin + 
glibenclamide 
4 1 1 0 0 0 0 3 
mono + 
insulin 
Metformin + 
insulin 
0 0 0 0 0 0 0 0 
 Gliclazide + 
insulin  
0 0 0 0 0 0 0 0 
 Glimepiride + 
insulin 
0 0 0 0 0 0 0 0 
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 Glibenclamide 
+ insulin 
0 0 0 0 0 0 0 0 
Dual + 
insulin 
Metformin + 
Gliclazide + 
insulin 
2 2 2 0 0 0 0 0 
 Metformin + 
glimepiride + 
insulin 
0 0 0 0 0 0 0 0 
 Metformin + 
glibenclamide 
+ insulin 
0 0 0 0 0 0 0 0 
Total  26 26 19 0 0 0 1 6 
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APPENDIX X: Treatment regimens and changes in glycated haemoglobin results outside target at the 
time of writing prescription 3 (n=86) 
Treatment 
regimen 
Anti-diabetic 
agent  
Prescription2 Prescription3 no 
change 
between 
P2&P3 
Daily 
dose 
increased 
Daily 
dose 
decreased 
Step-up 
regimen 
Step-
down 
regimen 
Lateral 
regimen 
change 
mono therapy Metformin 18 20 16 2 0 0 0 0 
 Gliclazide  2 2 1 0 0 0 0 1 
 Glimepiride 1 1 1 0 0 0 0 0 
 Glibenclamide 0 0 0 0 0 0 0 0 
Dual therapy Metformin + 
Gliclazide 
30 14 13 0 1 0 1 15 
 Metformin + 
glimepiride 
5 21 5 0 0 0 0 0 
 Metformin + 
glibenclamide 
7 4 4 0 0 0 1 2 
mono + 
insulin 
Metformin + 
insulin 
11 12 9 0 2 0 0 0 
 Gliclazide + 
insulin  
1 1 1 0 0 0 0 0 
 Glimepiride + 
insulin 
0 0 0 0 0 0 0 0 
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 Glibenclamide 
+ insulin 
0 0 0 0 0 0 0 0 
Dual + insulin Metformin + 
Gliclazide + 
insulin 
4 2 0 0 0 1 0 3 
 Metformin + 
glimepiride + 
insulin 
5 7 4 0 0 0 0 1 
 Metformin + 
glibenclamide 
+ insulin 
2 2 2 0 0 0 0 0 
Total  86 86 56 2 3 1 2 22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
103 
 
APPENDIX XI: Treatment regimens and  changes in fasting plasma glucose results within target at the 
time of writing prescription 2 (n=120) 
Treatment 
regimen 
Anti-diabetic 
agent  
Prescription 
1 
Prescription 
2 
no 
change 
between 
P1 & P2 
Dose 
increased 
Dose 
decreased 
Step-up 
regimen 
Step down 
regimen 
lateral 
regimen 
change 
Mono therapy Metformin 63 59 55 4 0 4 0 0 
 Gliclazide  7 5 5 0 0 1 0 1 
 Glimepiride 0 3 0 0 0 0 0 0 
 Glibenclamide 2 0 0 0 0 0 0 2 
Dual therapy Metformin + 
Gliclazide 
27 28 24 0 1 0 0 2 
 Metformin + 
glimepiride 
0 4 0 0 0 0 0 0 
 Metformin + 
glibenclamide 
9 7 5 0 0 0 0 4 
Mono + 
insulin 
Metformin + 
insulin 
8 8 8 0 0 0 0 0 
 Gliclazide + 
insulin  
0 1 0 0 0 0 0 0 
 Glimepiride + 
insulin 
0 0 0 0 0 0 0 0 
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 Glibenclamide 
+ insulin 
0 0 0 0 0 0 0 0 
Dual + 
insulin 
Metformin + 
Gliclazide + 
insulin 
4 4 2 0 1 0 1 0 
 Metformin + 
glimepiride + 
insulin 
0 1 0 0 0 0 0 0 
 Metformin + 
glibenclamide 
+ insulin 
0 0 0 0 0 0 0 0 
Total   120 120 99 4 2 5 1 9 
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APPENDIX XII: Treatment regimens and  changes in  fasting plasma glucose results outside target at the 
time of writing prescription 2 (n=433) 
Treatment 
regimen 
Anti-diabetic 
agent  
Prescription 
1 
Prescription2 no 
change 
between 
P1 & P2 
Dose 
increased 
Dose 
decreased 
Step- 
up 
regimen 
Step 
down 
regimen 
lateral 
regimen 
change 
Mono therapy Metformin 129 124 112 4 2 8 0 3 
 Gliclazide  14 13 11 1 0 1 0 1 
 Glimepiride 0 4 0 0 0 0 0 0 
 Glibenclamide 2 0 0 0 0 0 0 2 
Dual therapy Metformin + 
Gliclazide 
144 149 118 11 5 1 4 5 
 Metformin + 
glimepiride 
11 24 8 0 0 0 2 1 
 Metformin + 
glibenclamide 
35 20 17 1 0 0 1 16 
Mono + 
insulin 
Metformin + 
insulin 
43 46 32 5 3 0 0 3 
 Gliclazide + 
insulin  
6 5 4 0 1 0 0 1 
 Glimepiride + 
insulin 
0 0 0 0 0 0 0 0 
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 Glibenclamide 
+ insulin 
0 0 0 0 0 0 0 0 
Dual + insulin Metformin + 
Gliclazide + 
insulin 
39 37 21 5 3 1 3 6 
 Metformin + 
glimepiride + 
insulin 
3 6 2 1 0 0 0 0 
 Metformin + 
glibenclamide 
+ insulin 
7 5 4 1 0 0 0 2 
Total   433 433 329 29 14 11 10 40 
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APPENDIX XIII: Treatment regimens and  changes in fasting plasma glucose results within target at the 
time of writing prescription 3 (n=118) 
Treatment 
regimen 
Anti-diabetic 
agent  
prescription 
2 
prescription 
3 
no 
change 
between 
P2 & P3 
Daily 
dose 
increased 
Daily 
dose 
decreased 
Step-up 
regimen  
Step 
down 
regimen 
Lateral 
regimen 
change 
mono therapy Metformin 57 59 55 2 0 0 0 0 
 Gliclazide  4 4 1 1 0 0 0 2 
 Glimepiride 1 5 1 0 0 0 0 0 
 Glibenclamide 0 0 0 0 0 0 0 0 
Dual therapy Metformin + 
Gliclazide 
34 17 17 0 0 0 6 11 
 Metformin + 
glimepiride 
1 13 1 0 0 0 0 0 
 Metformin + 
glibenclamide 
3 3 1 0 0 0 1 1 
mono + 
insulin 
Metformin + 
insulin 
8 7 7 0 0 0 0 1 
 Gliclazide + 
insulin  
2 2 1 1 0 0 0 0 
 Glimepiride + 
insulin 
0 0 0 0 0 0 0 0 
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 Glibenclamide 
+ insulin 
0 0 0 0 0 0 0 0 
Dual + insulin Metformin + 
Gliclazide + 
insulin 
7 6 6 0 0 0 0 1 
 Metformin + 
glimepiride + 
insulin 
0 1 0 0 0 0 0 0 
 Metformin + 
glibenclamide 
+ insulin 
1 1 1 0 0 0 0 0 
  118 118 91 4 0 0 7 16 
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APPENDIX XIV: Treatment regimens and  changes in  fasting plasma glucose results outside target at 
the time of writing prescription 3 (n=419) 
Treatment 
regimen 
Anti-diabetic 
agent  
prescription 
2 
prescription 
3 
no 
change 
between 
P2 & P3 
Daily 
dose 
increased 
Daily 
dose 
decreased 
Step-up 
regimen  
Step 
down 
regimen 
Lateral 
regimen 
change 
mono therapy Metformin 121 127 113 3 0 5 0 0 
 Gliclazide  14 8 7 0 0 0 0 7 
 Glimepiride 6 10 5 0 1 0 0 0 
 Glibenclamide 0 0 0 0 0 0 0 0 
Dual therapy Metformin + 
Gliclazide 
136 79 65 8 1 0 0 62 
 Metformin + 
glimepiride 
26 90 21 1 0 0 1 3 
 Metformin + 
glibenclamide 
21 11 11 0 0 0 3 7 
mono + 
insulin 
Metformin + 
insulin 
44 45 37 3 1 0 0 3 
 Gliclazide + 
insulin  
4 3 3 0 0 0 0 1 
 Glimepiride + 
insulin 
0 0 0 0 0 0 0 0 
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 Glibenclamide 
+ insulin 
0 0 0 0 0 0 0 0 
Dual + insulin Metformin + 
Gliclazide + 
insulin 
35 19 10 3 1 0 0 21 
 Metformin + 
glimepiride + 
insulin 
8 25 7 0 0 0 1 0 
 Metformin + 
glibenclamide 
+ insulin 
4 2 1 0 0 0 0 3 
  419 419 280 18 4 5 5 107 
 
 
 
 
 
